

1 **Brain-heart-eye axis revealed by multi-organ imaging genetics and** 2 **proteomics**

3 Aleix Boquet-Pujadas¹, Filippos Anagnostakis¹, Michael R. Duggan³, Cassandra M. Joynes³,
4 Arthur W. Toga⁴, Zhijian Yang⁵, Keenan A. Walker³, the MULTI consortium[#], Christos
5 Davatzikos², Junhao Wen^{1,6,7*}

6

7 ¹Laboratory of AI and Biomedical Science (LABS), Columbia University, New York, NY, USA

8 ²Artificial Intelligence in Biomedical Imaging Laboratory (AIBIL), Center for AI and Data Science for Integrated
9 Diagnostics (AI²D), Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA

10 ³Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD,
11 USA

12 ⁴Laboratory of Neuro Imaging (LONI), Stevens Neuroimaging and Informatics Institute, Keck School of Medicine
13 of USC, University of Southern California, Los Angeles, California, USA

14 ⁵GE Healthcare, Bellevue, WA, USA

15 ⁶Center for Innovation in Imaging Biomarkers and Integrated Diagnostics (CIMBID), Department of Radiology,
16 Columbia University, New York, NY, USA

17 ⁷New York Genome Center (NYGC), New York, NY, USA

18

19 *Corresponding author:

20 Junhao Wen, junhao.wen89@gmail.com

21 622 W 168th St, New York, NY 10032

22 &Consortium representative: Junhao Wen

23

24 **Abstract**

25 Multi-organ research investigates interconnections among multiple human organ systems,
26 enhancing our understanding of human aging and disease mechanisms. Here, we used multi-
27 organ imaging ($N=105,433$), individual- and summary-level genetics, and proteomics
28 ($N=53,940$) from the UK Biobank, Baltimore Longitudinal Study of Aging, FinnGen, and
29 Psychiatric Genomics Consortium to delineate a brain-heart-eye axis via 2003 brain patterns of
30 structural covariance¹ (PSC), 82 heart imaging-derived phenotypes² (IDP) and 84 eye IDPs³⁻⁵.
31 Cross-organ phenotypic associations highlight the central autonomic network between the brain
32 and heart and the central visual pathway between the brain and eye. Proteome-wide associations
33 of the PSCs and IDPs show both within-organ specificity and cross-organ interconnections,
34 verified by the RNA and protein expression profiles of the 2923 plasma proteins. Pleiotropic
35 effects of common genetic variants are observed across multiple organs, and key genetic
36 parameters, such as SNP-based heritability, polygenicity, and selection signatures, are
37 comparatively evaluated among the three organs. A gene-drug-disease network shows the
38 potential of drug repurposing for cross-organ diseases. Colocalization and causal analyses reveal
39 cross-organ causal relationships between PSC/IDP and chronic diseases, such as Alzheimer's
40 disease, heart failure, and glaucoma. Finally, integrating multi-organ/omics features improves
41 prediction for systemic disease categories and cognition compared to single-organ/omics
42 features. This study depicts a detailed brain-heart-eye axis and highlights future avenues for
43 modeling human aging and disease across multiple scales. All results are publicly available at
44 <https://labs-laboratory.com/medicine/>.

45 Main

46 The brain, heart, and eye are key organs of human physiology, collectively orchestrating intricate
47 and vital processes essential for humans^{6,7}. Recent multi-organ research
48 endeavors^{8,9,10,11,12,13,14,15,16,17} have unveiled complex and synergistical relationships between
49 different human organ systems. These approaches hold the potential to unveil cross-organ
50 connections, elucidate the complex tapestry of human health and disease, and potentially pave
51 the road toward precision medicine¹⁸.

52 Imaging genetics¹⁹ integrates *in vivo* imaging data like magnetic resonance imaging
53 (MRI) with genetics, shedding light on disease mechanisms along underlying causal pathways²⁰
54 spanning from genetics to imaging-derived phenotypes (IDPs) and disease manifestations.
55 Additional omics data like transcriptomics, proteomics, and metabolomics²¹ can further enrich
56 our understanding of this causal pathway. The burgeoning development of machine learning has
57 led researchers to apply this technology to analyze brain MRI, yielding insights into brain aging
58 and disease. These include diagnosing and predicting diseases such as Alzheimer's disease
59 (AD)²², evaluating personalized treatment effectiveness like multiple sclerosis²³, and stratifying
60 patient populations into pathologically homogeneous subgroups²⁴, as well as in typical aging²⁵.
61 Both conventional and machine learning-derived brain imaging-derived phenotypes (IDPs) were
62 used in genome-wide association studies (GWAS)²⁶⁻²⁹, which were correlated with common and
63 rare single-nucleotide polymorphisms (SNPs). Likewise, cardiac MRI is pivotal in preventing,
64 diagnosing, and treating cardiovascular conditions related to the heart, such as ischaemic heart
65 disease³⁰. For example, recent studies^{2,31-35} have analyzed large-scale heart MRI data using
66 machine learning to extract heart IDPs to quantify cardiac structure and function. Heart imaging
67 GWAS was also performed to delineate the genetic architecture of these heart IDPs³⁶⁻³⁸. For
68 example, Aung and colleagues performed GWAS to identify 25 genomic loci associated with the
69 right ventricular structure and function of the heart³⁷. Finally, when integrated with machine
70 learning, optical coherence tomography (OCT) imaging has revolutionized diagnosing and
71 managing various eye diseases. For example, Zhou et al.³⁹ recently introduced RETFound, a
72 foundational model designed for retinal images. GWAS on eye OCT IDPs have also revealed
73 multiple genetic loci associated with the structure of the eye^{40,41}.


74 Mutli-organ research has revealed cross-organ connections^{8,9,10,11,12,13,14,15}, by allowing
75 researchers to delve into human aging and disease with a granularity that surpasses the single-
76 organ lens, thus better capturing the multifaceted disease etiology. A driving force behind this
77 was the advance of large-scale data consolidation initiatives, notably the UK Biobank (UKBB)⁴²,
78 which offered the scientific community multi-organ imaging and multi-omics data. In UKBB,
79 this collection of multi-organ imaging data encompasses brain MRI, heart MRI, eye OCT,
80 abdominal MRI (such as liver and pancreas scans), and whole-body dual-energy X-ray
81 absorptiometry imaging (Category ID:100003). For example, McCracken et al.¹¹ used multi-
82 organ imaging from UKBB to showcase the interrelationship between the heart, brain, and liver.
83 Zhao et al.⁸, in a recent study, reinforced the heart-brain connection by integrating genetic data,
84 unveiling insights into its genetic foundation. Yet, the brain IDPs utilized were predefined based
85 on the brain's neuroanatomy, encompassing volumetric assessments derived from specific
86 regions of interest (ROI) in T1-weighted MRI or diffusivity metrics related to white matter tracts
87 obtained from diffusion MRI. Machine learning has been integrated into imaging genetics and
88 has shown great potential to provide additional power in identifying new genomic loci^{1,43}. For
89 instance, Patel et al.⁴³ utilized a 3D convolutional autoencoder for training on T1-weighted and
90 T2-FLAIR brain MRIs from 6,130 UKBB participants, generating a 128-dimensional

91 representation termed ENDOs and showing additional discovery power compared to previous
92 predefined atlas-based brain IDPs. Similarly, in a prior study¹, we introduced sopNMF, a
93 stochastic optimization method for non-negative matrix factorization. This approach parcellates
94 the human brain into data-driven structural networks called patterns of structure covariance⁴⁴
95 (PSCs). Biologically, PSCs signify coordinated alterations across brain areas and individuals in a
96 data-driven approach – areas like Broca's cortex and Wernicke's area might collectively impact
97 individuals with motor speech dysfunction.

98 This study used individual-level imaging, genetic, and proteomic data from UKBB⁴²,
99 Baltimore Longitudinal Study of Aging (BLSA⁴⁵), and GWAS summary statistics from
100 FinnGen⁴⁶ and the Psychiatric Genomics Consortium⁴⁷ (PGC) to delineate the brain-heart-eye
101 axis (**Method 1**). To depict the neuroanatomical structures of the three organs, we used 2003
102 brain PSCs obtained from 39,567 brain T1-weighted MRI scans in our previous study¹, 82 heart
103 IDPs from 39,676 heart MRI scans analyzed by Bai et al.², and 84 eye IDPs from 64,317 eye
104 OCT images³⁻⁵ from UKBB (**Method 2** and **Supplementary Table 1**). We performed a
105 phenome-wide association study (PWAS, **Method 3**) to establish cross-organ phenotypic
106 landscapes between the 2003 brain PSCs, 82 heart IDPs, and 84 eye IDPs. A proteome-wide
107 association study (ProWAS, **Method 4**) was conducted to link the PSCs/IDPs to 2923 plasma
108 proteins (Olink) from UKBB and generate their expression profiles using organ/tissue-specific
109 RNA and protein data⁴⁸; the significant signals were scrutinized in an independent imaging
110 proteomics data (SomaScan) from BLSA. We then conducted GWASs to link the brain PSCs,
111 heart, and eye IDPs with common SNPs. Subsequently, we performed several post-GWAS
112 analyses to partially validate the genetic signals, including estimating key genetic parameters
113 (i.e., SNP-based heritability, polygenicity, and selection signature). A gene-drug-disease
114 network, genetic correlation, colocalization, and causal links between the brain PSCs, heart
115 IDPs, eye IDPS, and the respective diseases of each organ, were also established (**Method 5**).
116 Lastly, we evaluated the predictive capacity of the brain PSCs, heart and eye IDPs, as well as
117 their corresponding polygenic risk score (PRS), for 14 systemic disease categories and 8
118 cognitive scores (**Method 6**). Our analytic framework is illustrated in **Fig. 1**.

119
120

121 **Figure 1: Study workflow**



122
123 **a)** The 2003 multi-scale patterns of structural covariance (PSCs), 82 heart imaging-derived
124 phenotypes (IDPs) from magnetic resonance imaging (MRI), and 84 eye IDPs from optical
125 coherence tomography (OCT). **b)** Three main sets of analyses were conducted to demonstrate the
126 brain-heart-eye axis: *i)* phenotype-wide associations (PWAS) were performed between the 2003

127 brain PSCs, 82 heart IDPs, and 84 eye IDPs; *ii*) genome-wide association studies (GWAS) and
128 post-GWAS analyses were conducted between the brain PSCs, heart IDPs, eye IDPs, and
129 common genetic variants (SNPs), and *iii*) prediction ability of the brain PSCs, heart IDPs, eye
130 IDPs, and their PRS were assessed with AI to predict 14 systemic disease categories and 8
131 cognitive scores. All analyses used the Genome Reference Consortium Human Build 37
132 (GRCh37). Readers can visualize the 2003 brain PSCs via the BRIDGEPORT knowledge portal:
133 <https://labs-laboratory.com/bridgeport>. Detailed interpretations of the 84 eye IDPs and 82 heart
134 IDPs are publicly available at <https://labs-laboratory.com/medicine/eye> and [https://labs-](https://labs-laboratory.com/medicine/cardiovascular)
135 [laboratory.com/medicine/cardiovascular](https://labs-laboratory.com/medicine/cardiovascular).

136 Results

137 Phenotypic landscape of the 2003 brain PSCs, 82 heart IDPs, and 84 eye IDPs

138 To demonstrate the cross-organ phenotypic associations of the brain-heart-eye axis, we
139 conducted three primary PWASs linking the pair-wise imaging features of the three organs.

140 For the brain-heart PWAS, we found 16,158 significant associations (P -
141 value $<0.05/2003/82$; effective sample size: $21,948 < N < 23,548$; $-0.23 < r < 0.52$) after applying the
142 Bonferroni correction (**Fig. 2a** and **Method 3a**). The significant brain PSCs largely encompassed
143 deep subcortical structures, the bilateral anterior temporal pole, and the prefrontal cortex. For
144 example, C32_1 (visualization example: https://labs-laboratory.com/bridgeport/music/C32_1),
145 C64_1, and C128_1 delineated subcortical structures, such as the bilateral thalamus. Brain PSCs
146 like C32_3 exemplified the involvement of the bilateral anterior temporal pole. Brain PSC
147 (C128_2: https://labs-laboratory.com/bridgeport/music/C128_2) of the anterior insula was
148 significantly associated with several heart IDPs, such as the myocardial mass of the left ventricle
149 [LVM, $r=0.27$, $-\log_{10}(P\text{-value})=26.62$]. The observed brain imaging patterns largely align with
150 the central autonomic network⁴⁹, comprising the prefrontal cortex, amygdala, insular cortex,
151 anterior cingulate cortex, and brainstem. For the 82 heart IDPs, we identified 1313 significant
152 associations with the LVM (9%), 87 significant associations with the right ventricular end-
153 diastolic volume (RVEDV, 8%), and 55 associations with left ventricular mean myocardial wall
154 global thickness (WT_global, 7%). The detailed statistics of the brain-heart PWAS are presented
155 in **Supplementary eFile 1**. We conducted two sensitivity check analyses (**Supplementary eText**
156 **1a, eFile 2-3**) to validate the main PWAS results (**Method 3**). We obtained moderate
157 concordance rates (CR) regarding P -values in split-sample ($0.72 < CR\text{-}P < 0.99$) and sex-stratified
158 ($0.38 < CR\text{-}P < 0.91$) analyses. Moreover, the β values were highly correlated between the two
159 random splits ($r\text{-}\beta=0.97$) and female vs. male ($r\text{-}\beta=0.95$) PWASs. The brain-heart PWAS results
160 highlighted subcortical structures, the temporal pole, the insula cortex, the prefrontal cortex of
161 the brain, and the left ventricular mass of the heart.


162 For the brain-eye PWAS, We discovered 469 significant associations after applying the
163 Bonferroni correction (P -value $<0.05/2003/84$; effective sample size: $1284 < N < 4472$; -
164 $0.09 < r < 0.24$) (**Fig. 2b**). The prominent brain PSCs encompassed deep subcortical structures
165 (e.g., the thalamus) and the occipital cortex. For example, C32_1, C64_1, and C128_1 delineated
166 subcortical areas, including the lateral geniculate nucleus (LGN) and the hypothalamus. These
167 regions are crucial in the central projection of the retina, playing an essential role in normal
168 visual processing. Specifically, the LGN in the thalamus is a pivotal element of the mammalian
169 visual pathway, establishing connections with the optic nerve/fibers⁵⁰. Moreover, brain PSCs like
170 C32_28, C128_28, C256_179, and C512_489 exemplified primary cerebral cortex involvement
171 in the occipital lobe – the well-known visual cortex regions. For the 84 eye IDPs, we pinpointed
172 137 significant links with the left total macular volume (MvL, 29%), 87 and 83 significant
173 associations with the left/right average thickness of ganglion cells in the inner plexiform layer
174 (GcplR, 19%; GcplL, 18%), and 55 associations with the right total macular volume (MvR,
175 11%). Retinal ganglion cells, the projection neurons of the vertebrate retina, are pivotal in
176 conveying essential information from other retinal neurons to various brain regions within the
177 visual pathway⁵¹. In two sensitivity check analyses, we obtained moderate CRs regarding P -
178 values in split-sample ($CR\text{-}P=0.67$) and sex-stratified ($CR\text{-}P=0.78$) analyses, potentially due to
179 the limited sample sizes ($613 < N < 2348$). This was corroborated by the high correlation between
180 the β values of the PWASs across different splits ($r\text{-}\beta=0.99$) or sexes ($r\text{-}\beta=0.97$). Detailed results
181 for sensitivity check analyses can be found in **Supplementary eText 1b** and **eFile 4-6**. The

182 brain-eye PWAS revealed a distinct brain-eye phenotypic landscape that aligns closely with the
183 central visual pathway⁵².

184 For the heart-eye PWAS, the results did not survive the Bonferroni correction (P-
185 value<0.05/84/82; effective sample size: 1002<N<3926; -0.11<r<0.17). The most prominent
186 association was achieved between the RV stroke volume (RVSV) and macular thickness at the
187 right inner temporal subfield (MitR) (N=3821; Pearson's $r=0.16$; $-\log_{10}(\text{P-value})=5.09$). Overall,
188 the heart-eye phenotypic associations were less significant than those of the other two organs.
189 Detailed results can be found in **Supplementary eFile 7**.

190 We also performed a secondary PWAS (**Method 3b**) to link the PSCs/IDPs to 117
191 phenotypes of other organ systems. Detailed results can be found in **Supplementary eFigure 1**
192 and **eFile 8-10**. Finally, we mapped our brain PSCs with 119 conventional MUSE ROIs⁵³ using
193 three approaches to interpret the neuroanatomical structures of the brain PSCs. We also
194 discussed our brain PSC PWAS results compared to previous studies by Zhao et al.⁸ and Jaggi et
195 al.¹⁶ using conventional brain and heart IDPs and performed genetic correlation between our
196 2003 brain PSCs with 3874 conventional brain IDPs from Smith et al.²⁷ **Supplementary eText 2**
197 presents detailed results and discussion for these analyses, providing insights into the added
198 value of our brain PSCs.
199

200 **Figure 2: Phenotypic associations of the 2003 brain PSCs, 82 heart IDPs, and 84 eye IDPs.**



201
 202 **a)** The phenotypic associations between the 82 heart IDPs (left panel) and 2003 brain PSCs
 203 (middle panel) are shown after the Bonferroni correction ($P\text{-value} < 0.05/2003/82$; effective
 204 sample size: $21,948 < N < 23,548$; $-0.23 < r < 0.52$). For each PSC/IDP category, the percentage of
 205 the significant associations is displayed. In the right panel, we charted the significant PSC-IDP
 206 associations in the 3D brain space, providing the Pearson correlation coefficient (r) for
 207 representative brain PSCs with the heart IDP (LVM: left ventricle myocardial mass). **b)** The
 208 phenotypic associations between the 2003 brain PSCs (middle panel) and 84 eye IDPs (left
 209 panel) are shown. Significant results that survived the Bonferroni correction are presented ($P\text{-}$
 210 value $< 0.05/2003/84$; effective sample size: $1284 < N < 4472$; $-0.09 < r < 0.24$). We showed the high-
 211 level PSC/IDP categories for visualization purposes. Abbreviations: MtL: overall macular
 212 thickness (left); MoiL: macular thickness at the outer inferior subfield (left); MonL: macular
 213 thickness at the outer nasal subfield (left); MosL: macular thickness at the outer superior subfield
 214 (left); InL: the average thickness of the inner nuclear layer (left); GcplL: the average thickness
 215 of ganglion cells in the inner plexiform layer (left); MvL: total macular volume (left); MR:
 216 overall macular thickness (right); GcplR: the average thickness of ganglion cells in the inner
 217 plexiform layer (right); MvR: total macular volume (right); InR: the average thickness of the
 218 inner nuclear layer (right); RnfL: the average thickness of the retinal nerve fiber layer. MiiR:
 219 macular thickness at the inner inferior subfield (right); MonL: macular thickness at the outer
 220 nasal subfield (right); MisL: macular thickness at the inner superior subfield (left). For the

221 phenotypic association between the 82 heart IDPs and 84 eye IDPs, the results did not survive
222 the Bonferroni correction ($P\text{-value} < 0.05/84/82$; effective sample size: $1002 < N < 3977$; -
223 $0.11 < r < 0.15$). Readers can visualize the 2003 brain PSCs via the BRIDGEPORT knowledge
224 portal: <https://labs-laboratory.com//bridgeport>. Detailed interpretations of the 84 eye IDPs and 82
225 heart IDPs are publicly available at <https://labs-laboratory.com/medicine/eye> and [https://labs-](https://labs-laboratory.com/medicine/cardiovascular)
226 [laboratory.com/medicine/cardiovascular](https://labs-laboratory.com/medicine/cardiovascular).
227

228 **Proteomic map of the 2003 brain PSCs, 82 heart IDPs, and 84 eye IDPs**

229 To strengthen the cross-organ connection further, we performed three ProWASs delineating the
230 pair-wise associations between 2923 Olink plasma proteins and the 2003 brain PSCs, 82 heart
231 IDPs, and 84 eye IDPs (**Method 4a**). We then illustrated the organ-specific and cross-organ
232 interactions by assessing the proteins and RNA expression of the significant proteins using
233 organ/tissue-specific RNA and protein data (**Method 4b**).

234 For the brain ProWAS, we found 1282 significant associations between 558 brain PSCs
235 and 27 proteins (P -value $<0.05/2003/2923$; effective sample size: $51 < N < 4520$; $-0.42 < r < 0.55$)
236 after applying the Bonferroni correction (**Fig. 3a** and **Method 4a**). The most significant brain
237 PSCs (C32_2) showed associations with 10 different proteins. In contrast, the MOG protein had
238 the highest prominence, linking to 410 PSCs. We observed patterns of within-organ specificity
239 and cross-organ interactions. For instance, the KLK6 protein was associated with the brain PSC
240 and exhibited elevated expression levels in both RNA and protein data from brain tissues,
241 demonstrating within-organ specificity. In contrast, the MOG protein, also linked to the brain
242 PSC, was overexpressed in RNA and protein data from the kidney. Detailed statistics of the brain
243 ProWAS are presented in **Supplementary eFile 11**. Additionally, we found that 45 significant
244 brain PSC-protein pairs were replicated in BLSA^{45,54} with a stringent P -value threshold
245 ($<0.05/558/27$), although the BLSA has a smaller sample size ($N=924$) and used a different
246 proteomic platform (SomaScan); these two sets of estimated β values were significantly
247 correlated ($r=0.31$; P -value $=0.03$) and showed the same direction of associations
248 (**Supplementary eText 3** for more details).


249 For the eye ProWAS, We discovered 38 significant associations between 17 eye IDPs
250 and 13 proteins after applying the Bonferroni correction (P -value $<0.05/2923/84$; effective
251 sample size: $48 < N < 4250$; $-0.47 < r < 0.48$) (**Fig. 3b**). The eye IDP measuring the average thickness
252 of the left INL/RPE layer (InlRpeL) was significantly associated with 5 proteins, such as the
253 PLTP protein, which showed high expression values using protein and RNA data from eye-
254 related tissues. The detailed statistics of the eye ProWAS are presented in **Supplementary eFile**
255 **12**.

256 For the heart ProWAS, we identified 866 significant associations that survived the
257 Bonferroni correction between 29 heart IDPs and 196 proteins (P -value $<0.05/2923/82$; effective
258 sample size: $51 < N < 3462$; $-0.48 < r < 0.61$). The heart IDP (RVEDV: the end-diastolic volume of
259 the right ventricle) was associated with 128 proteins, such as the TGFA protein (**Fig. 3c**).
260 Detailed results can be found in **Supplementary eFile 13**.

261 We present the organ-specific expression at RNA gene expression levels for one
262 significant protein (i.e., the KLK6 protein) in **Fig. 3d** and provide a detailed discussion of these
263 ProWAS findings in the Discussion section. KLK6 was significantly associated with 123 brain
264 PSCs. For example, C32_1 was positively associated with KLK6 ($\beta=77.82\pm 10$; P -
265 value $=1.10\times 10^{-14}$). We then performed a protein-protein interaction analysis⁵⁵, showing its direct
266 and indirect interactions with other proteins, such as the KLK7 protein from the same family,
267 which may play similar roles in amyloid precursor protein, myelin basic protein, gelatin, casein,
268 and extracellular matrix proteins. Finally, we showed the RNA tissue-specific enrichment of this
269 protein in 50 different tissues using the HPA and GTEx data (**Method 4b**), with the most
270 prominent enrichment in the spinal cord (nTPM=475.6), midbrain (nTPM=148.9), and
271 hippocampus (nTPM=85.8) (**Fig. 3d**).

272

273 **Figure 3: Proteomics associations of the 2003 brain PSCs, 82 heart IDPs, and 84 eye IDPs.**



274 **a)** Proteome-wide associations between the 2003 brain PSCs (left panel) and 2923 plasma
 275 proteins (middle panel) are shown after the Bonferroni correction ($P\text{-value} < 0.05/2923/2003$;
 276 effective sample size: $51 < N < 4520$; $-0.42 < r < 0.55$). For each PSC or protein, the percentage of
 277

278 significant associations is proportional to the rectangle's height. In the right panel, we annotated
279 the protein expression profile in a specific tissue/organ by respective colors of the protein and
280 organ; dotted lines show secondary expression across different organs. **b)** The proteomics
281 associations between the 84 eye IDPs (left panel) and 2923 plasma proteins (middle panel) are
282 shown after the Bonferroni correction ($P\text{-value} < 0.05/2923/84$; effective sample size:
283 $48 < N < 4250$; $-0.47 < r < 0.48$). For each IDP or protein, the percentage of significant associations is
284 proportional to the rectangle's height. In the right panel, we annotated the protein expression in a
285 specific tissue/organ by respective colors of the protein and organ; dotted lines show secondary
286 expression across different organs. **c)** The proteomics associations between the 82 heart IDPs
287 (lower panel) and 2923 plasma proteins (middle panel) are shown after the Bonferroni correction
288 ($P\text{-value} < 0.05/2923/82$; effective sample size: $51 < N < 3462$; $-0.48 < r < 0.61$). The percentage of
289 significant associations for each IDP or protein is proportional to the rectangle's width. In the
290 upper panel, we annotated the protein expression level in a specific tissue/organ by respective
291 colors of the protein and organ; dotted lines showcase secondary expression across different
292 organs. **d)** An example of annotating the protein expression level using GTEx RNA-seq data in
293 50 different tissues for the KLK6 protein. We used the AlphaFold model to predict the protein
294 structure, followed by a protein-protein interaction network analysis. Additionally, we analyzed
295 the protein expression profiles across 50 diverse tissues to estimate their expression levels.
296 Readers can visualize the 2003 brain PSCs via the BRIDGEPORT knowledge portal:
297 <https://labs-laboratory.com/bridgeport>. Detailed interpretations of the 84 eye IDPs and 82 heart
298 IDPs are publicly available at <https://labs-laboratory.com/medicine/eye> and [https://labs-](https://labs-laboratory.com/medicine/cardiovascular)
299 [laboratory.com/medicine/cardiovascular](https://labs-laboratory.com/medicine/cardiovascular).
300

301 **Genetic architecture of the 2003 brain PSCs, 82 heart IDPs, and 84 eye IDPs**

302 Using genome-wide common genetic variants, we aimed to elucidate the genetic architecture of
303 the brain-heart-eye axis by conducting GWAS to identify shared genetic signals across the three
304 organs. Subsequently, we performed several post-GWAS analyses to validate these genetic
305 signals.


306 For the three primary GWASs (**Method 5a**) using European ancestry populations, we
307 identified 5854 ($P\text{-value} < 5 \times 10^{-8} / 2003$), 214 ($P\text{-value} < 5 \times 10^{-8} / 82$), and 1888 ($P\text{-value} < 5 \times 10^{-8} / 84$)
308 genomic locus-PSC/IDP associations for the 2003 brain PSCs, 82 heart, and 84 eye IDPs,
309 respectively. We denoted the genomic loci using their top lead SNPs (**Supplementary eMethod**
310 **1**) defined by FUMA; the genomic loci are presented in **Supplementary eFile 14-16**. We found
311 that 32, 94, and 29 common cytogenetic regions (based on the GRCh37 cytoband) were jointly
312 linked to the brain-heart, brain-eye, and heart-eye GWAS, respectively (**Fig. 4a-c**).

313 The primary GWAS conducted among populations of European ancestry demonstrated
314 robustness across several sensitivity analyses and underscored the necessity of collecting data
315 from non-European populations. We first calculated the genomic inflation factor (λ) and LDSC⁵⁶
316 intercept (b) for the 2003 brain PSC [$\lambda=1.095$ (1.007-1.233); $b=1.011$ (0.982-1.0467)], 82 heart
317 IDP GWASs [$\lambda=1.0649$ (1.0105-1.1459); $b=1.004$ (0.9815-1.0233)], and 84 eye IDP GWASs
318 [$\lambda=1.119$ (1.028-1.200); $b=1.019$ (0.991-1.045)]. All LDSC intercepts were close to 1, indicating¹
319 no substantial genomic inflation. We already scrutinized the brain GWAS in our previous study¹.
320 In the current study, we checked the robustness of the heart and eye IDP GWASs in five
321 additional sensitivity check analyses (**Method 5a**). For the heart IDP GWAS, we observed high
322 CRs based on the P-value and Pearson's r for the two sets of β values ($r\text{-}\beta$) in split-sample
323 ($0.82 < \text{CR-P} < 0.97$; $r\text{-}\beta=0.94$) and sex-stratified ($0.76 < \text{CR-P} < 0.94$; $r\text{-}\beta=0.78$) sensitivity analyses.
324 Furthermore, our GWAS β values were highly correlated with those from a prior heart IDP
325 GWAS by Zhao et al.⁸ ($r\text{-}\beta=0.90$). However, our GWAS's generalizability to non-European
326 ancestries was limited due to limited sample sizes in non-European populations ($0.02 < \text{CR-}$
327 $\text{P} < 0.50$) based on P-values, underscoring the need to increase sample sizes for future GWAS in
328 underrepresented ethnic groups ($r\text{-}\beta=0.84$) (**Supplementary eText 4a** and **eFile 17-20**). For the
329 eye IDP GWAS, we observed high CRs based on the P-values and Pearson's $r\text{-}\beta$ values across
330 split-sample ($0.86 < \text{CR-P} < 0.98$; $r\text{-}\beta=0.97 \pm 0.04$), sex-stratified ($0.80 < \text{CR-P} < 0.95$; $r\text{-}$
331 $\beta=0.96 \pm 0.11$), and GWAS method-specific ($\text{CR-P}=1$ between PLINK linear model and
332 fastGWA⁵⁷ linear mixed model; $r\text{-}\beta=0.99 \pm 0.0008$) sensitivity analyses. In addition, our GWAS
333 reproduced discoveries from a previous eye IDP GWAS study by Zhao et al.⁵⁸ ($\text{CR-P}=0.72$; $r\text{-}$
334 $\beta=0.996$). The generalizability of our GWAS to non-European ancestries was restricted ($0.11 <$
335 $\text{CR-P} < 0.63$) according to the P-values, possibly due to limited sample sizes. This was supported
336 by the high correlation ($r\text{-}\beta=0.95$) observed between the two sets of β estimates (**Supplementary**
337 **eText 4b** and **eFile 21-25**). Manhattan and QQ plots are publicly available at the MEDICINE
338 knowledge portal: <https://labs-laboratory.com/medicine/>. All subsequent post-GWAS analyses
339 utilized the primary GWAS results from European ancestry cohorts.

340 To uncover the phenome-wide associations of the heart and eye IDP-linked genomic loci
341 in the previous literature, we performed a PheWAS (**Method 5b** and **Supplementary eText 5**)
342 look-up analysis using the GWAS Atlas⁵⁹ platform for these top lead SNPs. This identified 2939
343 and 8493 previous SNP-trait associations in prior GWASs for the heart and eye IDP GWASs,
344 respectively, as detailed in **Supplementary Figure 2**, **eText 5**, and **eFile 26-27**.

345

346 **Figure 4: Genome-wide associations of the 2003 brain PSCs, 82 heart IDPs, and 84 eye**
 347 **IDPs**



348 **a)** Cytogenetic regions where the genomic region was jointly linked to the heart IDPs and brain
 349 PSCs. Bonferroni correction was applied to denote significant genomic loci associated with the
 350 brain PSCs ($P\text{-value} < 5 \times 10^{-8} / 2003$) and heart IDPs ($P\text{-value} < 5 \times 10^{-8} / 82$). **b)** Cytogenetic regions
 352 where the genomic region was jointly linked to the eye IDPs and brain PSCs. Bonferroni
 353 correction was applied to denote significant genomic loci associated with the brain PSCs (P -

354 value $<5 \times 10^{-8}/2003$) and eye IDPs (P-value $<5 \times 10^{-8}/84$). c) Cytogenetic regions where the
355 genomic region was jointly linked to eye IDPs and heart IDPs. Bonferroni correction was applied
356 to denote significant genomic loci associated with the heart IDPs (P-value $<5 \times 10^{-8}/82$) and eye
357 IDPs (P-value $<5 \times 10^{-8}/84$). Readers can visualize the 2003 brain PSCs via the BRIDGEPORT
358 knowledge portal: <https://labs-laboratory.com/bridgeport>. Detailed interpretations of the 84 eye
359 IDPs and 82 heart IDPs are publicly available at <https://labs-laboratory.com/medicine/eye> and
360 <https://labs-laboratory.com/medicine/cardiovascular>.
361
362

363 **SNP-based heritability estimates of the 2003 brain PSCs, 82 heart IDPs, and 84 eye IDPs**

364 We computed the SNP-based heritability to quantify the proportion of phenotypic variance
365 attributable to common genetic variants across the genome and organs. Among the 2003 brain
366 PSCs, the GCTA⁶⁰ software revealed significant SNP-based heritability in 1897 PSCs
367 ($h^2=0.30\pm 0.16$; P-value $<0.05/2003$) (**Method 5c**). Among the 82 heart IDPs, 80 demonstrated
368 significant heritability estimates ($h^2=0.25\pm 0.12$; P-value $<0.05/82$) (**Fig. 5b**), and all 84 eye IDPs
369 demonstrated significant heritability estimates ($h^2=0.44\pm 0.12$; P-value $<0.05/84$) (**Fig. 5a-c**).

370 For the brain PSCs, The heritability estimates spanned from a coarse to a fine scale (C32
371 to C1024), with the highest h^2 observed at the C32 scale ($h^2=0.45\pm 0.16$; P-value $<1.57\times 10^{-8}$) and
372 the lowest h^2 at the C256 scale ($h^2=0.24\pm 0.16$; P-value $<2.27\times 10^{-5}$). The heritability estimates
373 varied across the 82 heart IDPs for the 6 high-level categories, with the highest h^2 observed for
374 the ascending aorta (AA, $h^2=0.60\pm 0.20$; P-value $<1.22\times 10^{-56}$) and the lowest h^2 for the IDPs of
375 the left ventricle (LV, $h^2=0.21\pm 0.09$; P-value $<1.42\times 10^{-5}$). The heritability estimates also varied
376 across the 84 eye IDPs for the 11 high-level categories, with the highest h^2 observed for macular
377 volume (MV, $h^2=0.68\pm 0.0008$; P-value $<1.47\times 10^{-36}$) and the lowest h^2 for the external limiting
378 membrane layer (ELM) and inner & outer segment (ISOS) layers (ELM/ISOS, $h^2=0.30\pm 0.04$; P-
379 value $<1.24\times 10^{-81}$).

380 The detailed statistics of the SNP-based heritability estimates are presented in
381 **Supplementary eFile 28-29**. The results generated by LDSC are detailed in **Supplementary**
382 **eFile 30-31** for the heart and eye IDPs, respectively. Overall, LDSC-derived results using
383 summary-level data were lower than (e.g., heart PSCs: $h^2=0.14\pm 0.07$; $h^2=0.22\pm 0.06$) but highly
384 correlated with ($r=0.95$; P-value $=4.18\times 10^{-42}$; $r=0.88$; P-value $<3.79\times 10^{-28}$) the GCTA estimates,
385 which used individual-level data. This was consistent with previous observations on brain IDP
386 GWASs^{61,26} which may be attributed to the different model assumptions and LD information of
387 different approaches⁶². Furthermore, our GCTA-based h^2 estimates for the heart and eye IDPs
388 were highly correlated with those obtained from Zhao et al.⁸ (heart IDPs: $N=82$ overlapping
389 IDPs, $r=0.91$, P-value $<1\times 10^{-10}$) and Zhao et al.⁵⁸ (eye IDPs: $N=46$ overlapping IDPs, $r=0.99$, P-
390 value $<1\times 10^{-10}$), both using GCTA (**Supplementary eFigure 3**).


391
392 **Selection signatures and polygenicity estimates of the 2003 brain PSCs, 82 heart IDPs, and**
393 **84 eye IDPs**

394 To understand the evolutionary processes of these PSCs/IDPs, specifically regarding how traits
395 evolve and adapt over time through natural selection and genetic variation, we used the
396 SBayesS⁶³ method to compute the selection signature (S) and polygenicity (Pi) for the 2003 brain
397 PSCs, 82 heart IDPs, and 84 eye IDPs (**Method 5d**). A signature of negative (or purifying)
398 selection prevents mutations with significant harmful effects from becoming prevalent in the
399 population, while positive selection promotes the propagation of those with beneficial effects.

400 We obtained selection signature estimates of $S=-0.32\pm 0.22$, $S=-0.40\pm 0.20$, and $S=-$
401 0.69 ± 0.20 for the 2003 brain PSCs, 82 heart IDPs, and 84 eye IDPs (pairwise estimates P-value
402 < 0.001). Similarly, we observed polygenicity estimates of $Pi=0.040\pm 0.015$, $Pi=0.043\pm 0.014$,
403 and $Pi=0.014\pm 0.021$ for the 2003 brain PSCs, 82 heart IDPs, and 84 eye IDPs. These findings
404 offer a comparative assessment of critical genetic metrics to elucidate the genetic code governing
405 the three organs (**Fig. 5d-f**). Detailed statistics are presented in **Supplementary eFile 32-34**.

406

407 **Figure 5: Key genetic parameters of the 2003 brain PSCs, 82 heart IDPs, and 84 eye IDPs**



408
 409 **a-c)** The SNP-based heritability (h^2) was estimated using the GCTA software for the 2003 brain
 410 PSCs (C32-1024), 82 heart IDPs, and 84 eye IDPs. **d-f)** The selection signature (S) was
 411 estimated using the SBayesS software for the 2003 brain PSCs, 82 heart IDPs, and 84 eye IDPs.
 412 **g-i)** The polygenicity (P_i) was estimated using the SBayesS software for the 2003 brain PSCs, 82
 413 heart IDPs, and 84 eye IDPs. **j-l)** The tissue-specific partitioned heritability using gene
 414 expression and chromatin data was estimated using the LDSC software for the 2003 brain PSCs,
 415 82 heart IDPs, and 84 eye IDPs. We further categorized brain PSCs into different scales of the C
 416 parameters. The 82 heart IDPs are divided into 6 segmented heart regions: the left ventricle
 417 (LV), right ventricle (RV), left atrium (LA), right atrium (RA), descending aorta (DA), and
 418 ascending aorta (AA). The error bar denotes the standard error of the estimate of the mean. The
 419 84 eye IDPs were classified into 11 high-level phenotype categories. Readers can visualize the
 420 2003 brain PSCs via the BRIDGEPORT knowledge portal: [https://labs-](https://labs-laboratory.com/bridgeport)
 421 [laboratory.com/bridgeport](https://labs-laboratory.com/bridgeport). Detailed interpretations of the 84 eye IDPs and 82 heart IDPs are
 422 publicly available at <https://labs-laboratory.com/medicine/eye> and [laboratory.com/medicine/cardiovascular](https://labs-

 423 <a href=).

424
 425 **Tissue-specific enrichment of partitioned heritability of the 2003 brain PSCs, 82 heart**
 426 **IDPs, and 84 eye IDPs**

427 To provide additional biological validation for our GWAS discoveries of this brain-heart-eye
428 axis, we conducted partitioned heritability analyses⁶⁴ (**Method 5e**) to estimate the heritability
429 enrichment of genetic variants regarding 205 tissue-specific gene expression data (e.g., lung,
430 brain, and liver)⁶⁵ and 489 tissue-specific chromatin annotation data (e.g., heart-
431 atrial_H3K4me3)^{66,67} (**Fig. 5j-l**).

432 For the brain PSCs, we found 30 significant heritability enrichment (P-value <
433 0.05/205/489) in various brain tissues (e.g., angular gyrus and ganglion eminence) and
434 musculoskeletal tissues (e.g., fetal muscle leg) at different chromatin states (**Fig. 5j**). For
435 example, C32_8 showed significant heritability enrichment (P-value= 1.33×10^{-8}) in ganglion
436 eminence derived from primary culture neurospheres of peaks for trimethylated lysine 4 on
437 histone H3 (H3K4me3). For the heart IDPs, 12 significant heritability enrichment was found in
438 multiple heart tissues in the H3K4me1 (e.g., P-value= 9.06×10^{-5} for the fetal heart and the end-
439 systolic volume of the LV), and acetylated lysine 27 on histone H3 (H3K27ac, P-value= 1.78×10^{-8}
440 for the aorta and the descending aorta maximum area; **Fig. 5k**). For the eye IDPs, we found that
441 4 significant heritability enrichment in retina-related tissues and fetal muscle (**Fig. 5l**). Detailed
442 statistics are presented in **Supplementary eFile 35-37**. Those organ-specific enrichment patterns
443 largely provide biological validation of our primary GWAS results.

444
445


446 **Gene-drug-disease network highlights drug repurposing potential for cross-organ diseases**

447 We conducted a gene-drug-disease enrichment analysis⁶⁸ using genes associated with the 2003
448 brain PSCs, 82 heart IDPs, and 84 eye IDPs within the targeted gene sets of drug categories from
449 the DrugBank database⁶⁹. This analysis constructed a gene-drug-disease network to identify
450 potentially repurposable drugs, which has been shown to increase drug development success in
451 the literature^{70,71} (**Method 5f**).

452 For the brain PSCs, the gene-drug-disease network identified 1207 significant pairs of
453 gene-drug-disease interactions between 57 unique brain PSCs, 27 genes, and 78 ICD disease
454 categories. For the eye IDPs, we found 327 significant interactions between 4 unique IDPs, 8
455 genes, and 33 ICD disease categories. Finally, for the heart IDPs, we identified 8 significant
456 interactions between one gene, two IDPs, and 1 ICD disease category (**Fig. 6**). Here, we
457 showcased several drugs and/or small molecules. For example, the *GALR3* gene linked to the
458 brain PSC (C32_2) served as the target gene for *HT-2157* (NCT number: NCT01413932; status:
459 completed). This drug, a selective non-peptide antagonist for the GAL-3 receptor, was tested for
460 treating major depressive disorder (ICD: F00-09). Another example was the *MAPT* gene
461 associated with both brain PSC (e.g., C128_106) and eye IDP (e.g., GCPL), which was the target
462 gene for *AL-408* (small molecule drug) treating cerebrovascular disorders and cognition
463 disorders (G40-47 and G10-14). The *MAPT* gene was also used to develop another drug,
464 davunetide, which has been investigated in clinical trials aimed at treating various diseases
465 related to the central nervous system, including progressive nonfluent aphasia, progressive
466 supranuclear palsy, corticobasal degeneration syndrome, and frontotemporal dementia with
467 parkinsonism. The *CCL11* gene associated with the brain PSC (C1024_275) was used to develop
468 the drug bertilimumab, treating multiple eye diseases, including glaucoma (ICD-code: H).
469 Finally, the heart IDP-related (LA maximum/minimum volum) gene *DMPK* was enriched in
470 several drugs, including *isis-dmpk*, for treating diseases of the myoneural junction and muscle
471 (ICD-code: G70-G73). Detailed results are presented in **Supplementary eFile 38-40**.

472
473

474 **Figure 6: The gene-drug-disease network of the 2003 brain PSCs, 82 heart IDPs, and 84 eye**
 475 **IDPs**



476
 477 The gene-drug-disease network reveals a broad spectrum of gene, drug, and disease interactions
 478 across the 2003 brain PSCs, 84 eye IDPs, 82 heart IDPs, and diseases beyond the three organs.
 479 The ICD code icons symbolize disease categories linked to the primary organ systems. All
 480 presented genes passed the FDR-corrected P-value threshold and were pharmaco-genetically
 481 associated with drug categories in the DrugBank database. Abbreviation: ICD: International
 482 Classification of Diseases. We showcased four representative drugs from the genes linked to the
 483 three organs.
 484

485 **Genetic correlation between the 2003 brain PSCs, 82 heart IDPs, and 84 eye IDPs**

486 We estimated the pairwise PSCs/IDPs genetic correlation⁵⁶ (g_c , **Method 5g**) between the three
487 organs. This analysis further supports the cross-organ interconnections and echos their
488 phenotypic associations, supporting Cheverud's Conjecture⁷².

489 For the brain-heart correlation, we found 30 significant genetic correlations [$g_c=0.31$ (-
490 0.60, 0.38)] after applying the Bonferroni correction (P-value < 0.05/2003) (**Fig. 7a** and
491 **Supplementary eFile 41**). The significant genetic correlations largely encompassed deep
492 subcortical structures, the inferior frontal cortex, the insula cortex, and the temporal pole. For
493 example, the largest negative correlation was found between the circumferential strain AHA_2
494 (Ecc_AHA_2) of the LV and C256_57 ($g_c=-0.60\pm 0.13$; P-value= 7.16×10^{-6}) and the strongest
495 positive correlation between the descending aorta distensibility (Dao_AD) and C1024_827
496 ($g_c=0.38\pm 0.09$; P-value= 1.32×10^{-5}). For the heart IDPs, the most enriched associations were
497 linked to the ascending and descending aorta (97%).

498 For the brain-eye correlation, we found 18 significant positive genetic correlations
499 ($g_c=0.19\pm 0.01$) after applying the Bonferroni correction (P-value < 0.05/2003) (**Fig. 7b** and
500 **Supplementary eFile 42**). These correlations included GcplL of the eye and brain regions
501 covering deep subcortical structures. Examples were between GcplL and C1024_963
502 ($g_c=0.21\pm 0.04$; P-value= 1.65×10^{-6}) and between GcplR and C32_1 ($g_c=0.18\pm 0.04$; P-
503 value= 4.98×10^{-5}). The PSCs of the visual cortex exhibited signals of lesser significance, which
504 did not withstand the Bonferroni correction. This could be attributed to potential limitations in
505 power when using GWAS summary statistics via LDSC compared to the phenotypic associations
506 derived from raw phenotype data. However, our results evidenced a substantial alignment
507 between the phenotypic and genetic correlations for the pairwise PSC-IDP. For example, GcplL
508 showed a significant phenotypic correlation ($r=0.11$; P-value= 1.10×10^{-12}) with C32_1, echoing
509 their genetic correlation mentioned above ($g_c=0.18\pm 0.04$; P-value= 4.95×10^{-5}).

510 For the heart-eye correlation, we found only 3 significant positive genetic correlations
511 after Bonferroni correction (P-value < 0.05/84). The left macular thickness at the outer temporal
512 subfield (MotL) was genetically correlated with the RA stroke volume (RASV) ($g_c=0.36\pm 0.09$;
513 P-value= 4.00×10^{-5}) and RA maximum volume (RAV_max) ($g_c=0.32\pm 0.08$; P-value= 6.00×10^{-5}).
514 The left macular thickness at the inner temporal subfield (MitL) was genetically correlated with
515 the RA maximum volume (RAV_max) ($g_c=0.30\pm 0.08$; P-value= 3.00×10^{-4}) (**Supplementary**
516 **eFile 43**).

517

531 locus (8p23.1) between the right inner nuclear layer thickness at the inner temporal subfield
532 (InIR) and the LA stroke volume (LASV). **f)** The *Brain2Heart* causal relationship tested 2003
533 brain PSCs as exposure variables and 45 heart diseases (code: I9) as outcome variables; the
534 *Heart2Brain* causal link is established between 82 heart IDPs as exposure variables and 41 brain
535 diseases as outcome variables. **g)** The *Brain2Eye* causal relationship tested 2003 brain PSCs as
536 exposure variables and 32 eye diseases (code: H7) as outcome variables; the *Eye2Brain* causal
537 link is established between 84 eye IDPs as exposure variables and 41 brain diseases as outcome
538 variables. **h)** The *Heart2Eye* causal relationship tested 82 heart IDPs as exposure variables and
539 32 eye diseases (code: H7) as outcome variables; the *Eye2Heart* causal link is established
540 between 84 eye IDPs as exposure variables and 45 heart diseases as outcome variables. Solid
541 arrow lines represented significant results with more stringent Bonferroni correction (i.e., P-
542 value < 0.05/N, where N represents the larger number of IDPs/PSCs/diseases), and dotted arrow
543 lines for a less stringent correction (i.e., P-value < 0.05/M, where M represents the smaller number
544 of IDPs/PSCs/diseases). The symbols + and – signify positive and negative causal associations
545 between the traits tested. Readers can visualize the 2003 brain PSCs via the BRIDGEPORT
546 knowledge portal: <https://labs-laboratory.com/bridgeport>. Detailed interpretations of the 84 eye
547 IDPs and 82 heart IDPs are publicly available at <https://labs-laboratory.com/medicine/eye> and
548 <https://labs-laboratory.com/medicine/cardiovascular>.

549 550 **The genetic colocalization between the 2003 brain PSCs, 82 heart IDPs, and 84 eye IDPs**

551 To identify potential shared causal variants, we applied the Approximate Bayes Factor
552 colocalization⁷³ method between each PSC-IDP and IDP-IDP pair of the three organs (**Method**
553 **5h**).

554 For the brain-heart colocalization, we found 1822 colocalization signals using the
555 suggested posterior possibility threshold⁷³ (PP.H4.ABF > 0.8, which tests the hypothesis H4: a
556 shared causal variant is associated with both traits) (**Supplementary eFile 44**). Genetic
557 colocalization was observed at the genomic locus (2p22.2) between the mean myocardial wall
558 thickness AHA_4 (WT_AHA_4) of the LV and C64_45 of the brain (PP.H4.ABF = 0.9804). This
559 discovery highlights the potential causal variant (rs62132550), aligning with the physical
560 position of the *STRN* gene. SNPs in strong linkage disequilibrium with this causal SNP have
561 previously shown associations with diverse traits documented in the GWAS Catalog,
562 encompassing brain morphological features like white matter diffusivity and cortical surface
563 area, as well as traits such as red cell distribution width and alanine transaminase levels (**Fig. 7c**).

564 For the brain-eye colocalization, we found 5368 colocalization signals (**Supplementary**
565 **eFile 45**). We illustrate this at the locus (3p21.31) between the right macular thickness at the
566 inner temporal subfield (MitR) and C32_29 of the brain, which outlines the posterior cortex of
567 the brain (PP.H4.ABF = 0.9966, **Fig. 7d**). This discovery highlights the potential causal variant
568 located at chr3:45795731, aligning with the physical position of the *SLC6A20* gene. SNPs in
569 strong linkage disequilibrium with this causal SNP have previously been linked to various traits
570 in the GWAS Catalog⁷⁴. Notably, the top lead SNP (rs17279437) was associated with macular
571 measurement⁷⁵ and retinal disorders⁷⁶, and another SNP (rs73058498; mapped gene: *SACMIL*)
572 was associated with brain morphology⁷⁷. Other SNPs within this locus were also previously
573 associated with body mass index⁷⁸ and systolic blood pressure⁷⁹.

574 For the heart-eye colocalization, we identified 538 colocalization signals
575 (**Supplementary eFile 46**). For example, we showed one locus (8p23.1) between the right inner
576 nuclear layer thickness at the inner temporal subfield (InIR) and the LA stroke volume (LASV);

577 PP.H4.ABF=0.9980, **Fig. 7e**). This discovery highlights the potential causal and top lead variant
578 (rs2975648), mapping to the *MSRA* gene. SNPs in strong linkage disequilibrium with this causal
579 SNP have been linked to neuroticism, triglycerides level, and smoking initiation in previous
580 literature.

581

582 **Cross-organ causal network between the brain, heart, and eye**

583 We established 6 bi-directional causal networks between the PSC/IDPs and disease endpoints of
584 the three organs using FinnGen⁴⁶; PGC⁴⁷ data were used as replications for the brain-related
585 causal relationships. We established these networks by employing two-sample Mendelian
586 randomization analyses⁸⁰ (**Method 5i**).

587 Within the *Brain2Heart* network, we found potential causal relationships from C512_352
588 to heart failure (I9_HEARTFAILURE) [P-value=8.29x10⁻⁵<0.05/603 PSCs; OR (95% CI)=1.28
589 (1.14, 1.46); number of IVs=9], C256_7 to varicose veins (I9_VARICAE) [P-value=2.70x10⁻⁵;
590 OR (95% CI)=1.17 (1.08, 1.25); number of IVs=21], C1024_726 to diseases of vein, lymphatic
591 vessels, and lymph nodes (I9_DISVEINLYMPH) [P-value=1.20x10⁻⁵; OR (95% CI)=0.83 (0.77,
592 0.90); number of IVs=9], and C1024_880 to hypertension (I9_HYPTENSESS) [P-
593 value=1.50x10⁻⁵; OR (95% CI)=1.09 (1.05, 1.13); number of IVs=28] (**Fig. 7f**).

594 Within the *Heart2Brain* network, we found several significant causal signals (P-
595 value=0.05/41 unique brain disease endpoints). We found potential causality from the global
596 circumferential strain of the LV (Ecc_global) to recurrent depression (F5_DEPRESSION) [P-
597 value=5.60x10⁻⁵; OR (95% CI)=0.78 (0.70, 0.88); number of IVs=11], the Dao_min to migraine
598 with aura (G6_MIGRANE_WITH_AURA) [P-value=1.50x10⁻⁴; OR (95% CI)=1.27 (1.12, 1.43);
599 number of IVs=16], the Dao_max to migraine with aura (G6_MIGRANE_WITH_AURA) [P-
600 value=1.90x10⁻⁴; OR (95% CI)=1.28 (1.12, 1.45); number of IVs=16], and the global mean of
601 the myocardial wall thickness of LV (WT_global) to AD [P-value=1.22x10⁻³; OR (95%
602 CI)=0.70 (0.56, 0.87); number of IVs=8] (**Fig. 7f**).

603 Within the *Brain2Eye* network, we identified potential causal relationships from
604 C512_479 (medial orbital frontal region) to glaucoma [P-value=6.16x10⁻⁶<0.05/603 PSCs; OR
605 (95% CI)=1.35 (1.18, 1.53); number of IVs=7] and primary open-angle glaucoma (POAG) [P-
606 value=1.12x10⁻⁵; OR (95% CI)=1.67 (1.33, 2.11); number of IVs=7] (**Fig. 7g**).

607 Within the *Eye2Brain* network, we found potential causal signals from the right retinal
608 pigment epithelium (RPE) thickness at the outer superior subfield (RpeOsR) to the use of
609 hypnotics and sedatives [P-value=2.26x10⁻⁴<0.05/75 IDPs; OR (95% CI)=1.09 (1.04, 1.13);
610 number of IVs=9], the left macular thickness at the inner superior subfield (MisL) to depression
611 [P-value=4.08x10⁻⁴; OR (95% CI)=1.14 (1.06, 1.22); number of IVs=27], the left macular
612 thickness at the inner inferior subfield (MiiL) to sleep apnoea [P-value=4.53x10⁻⁴; OR (95%
613 CI)=1.11 (1.05, 1.17); number of IVs=29], and the left INL/ELM thickness at the inner subfield
614 (INLEMLiL) to AD [P-value=1.21x10⁻³<0.05/41; OR (95% CI)=0.83 (0.74, 0.93); number of
615 IVs=56]. Notably, this INLEMLiL-AD causal relationship was independently replicated using
616 the AD case-control GWAS⁸¹ from the PGC [P-value=8.31x10⁻³; OR (95% CI)=0.93 (0.88,
617 0.98); number of IVs=64] (**Fig. 7g**).

618 For the *Heart2Eye* network, we found potential causal relationships from the descending
619 aorta maximum area (Dao_max) to strabismus (H7_STRABOTH) [P-value=5.10x10⁻⁴<0.05/32
620 eye diseases; OR (95% CI)=1.27 (1.11, 1.45); number of IVs=16] and disorders of ocular
621 muscles, binocular movement, accommodation and refraction (H7_OCUMUSCLE) [P-
622 value=5.40x10⁻⁴; OR (95% CI)=1.17 (1.07, 1.28); number of IVs=16]. Causation was also

623 established from the descending aorta minimum area (Dao_min) to strabismus
624 (H7_STRABOTH) [P-value= 8.80×10^{-4} ; OR (95% CI)=1.24 (1.09, 1.40); number of IVs=16] and
625 disorders of ocular muscles, binocular movement, accommodation and refraction
626 (H7_OCUMUSCLE) [P-value= 5.80×10^{-4} ; OR (95% CI)=1.16 (1.06, 1.26); number of IVs=16].
627 Finally, ascending aorta maximum area (Aao_max) to glaucoma (H7_GLAUCOMA) [P-
628 value= 8.60×10^{-4} ; OR (95% CI)=0.89 (0.84, 0.95); number of IVs=38] (**Fig. 7h**).

629 For the *Eye2Heart* network, we identified potential causal relationship from the left
630 average elmsos thickness (ElmsosL) to coronary atherosclerosis (I9_CORATHER) [P-
631 value= $5.40 \times 10^{-4} < 0.05/75$ eye IDPs; OR (95% CI)=1.17 (1.07, 1.28); number of IVs=21] (**Fig.**
632 **7h**). Details of the results, including all five different Mendelian randomization estimators, are
633 shown in **Supplementary eFile 47-52**. Detailed quality check analyses for each significant
634 causal relationship are presented in **Supplementary eFigure 4-23**. **Supplementary eText 6**
635 compares our causal analyses with those conducted in the previous studies by Zhao et al.⁸ and
636 Lin et al.⁸².

637 **Multi-organ features improve prediction for 14 systemic diseases and 8 cognitive scores**

638 We assessed the enhanced predictive capabilities of integrating the brain PSCs, heart IDPs, eye
639 IDPs, and their respective PRSs (**Method 5j**), compared to single-organ/omics features. This
640 assessment aimed to predict 14 systemic disease categories based on the ICD-10 code and 8
641 cognitive scores in both univariate and multivariate machine learning and statistical models. The
642 definition of patient and healthy control groups is detailed in **Method 6** and **Supplementary**
643 **eTable 2**. Of note, these tasks aim to test our hypothesis that multi-organ, multi-omics data can
644 improve model performance compared to single-organ/omics data. The overall model
645 performance is modest, considering the inherent difficulty of the tasks, the heterogeneity of the
646 patient groups, and the use of baseline machine learning models. In addition, we did not include
647 proteomics data because of their high missing value rates across individuals and proteins.


648 We first evaluated the prediction power (i.e., the incremental R^2 ; **Method 6a**) of the
649 individual PSC/IDP/PRS to predict the 14 disease categories. Overall, we found that the most
650 predictive features corresponded to the diseases of their respective primarily affected organs. For
651 example, the 10 representative brain PSCs and 10 brain PSC-PRSs demonstrated the strongest
652 predictive capacity for mental and behavioral disorders (ICD-10 code: F). Detailed results and
653 interpretation are presented in **Supplementary eText 7**, **eFigure 24**, and **eFile 53-55**.

654 We then evaluated the predictive capacity of cross-organ imaging features (IDPs or
655 PSCs) and their respective PRSs in classifying the 14 disease categories by combining different
656 sets of features for different organs (**Method 6b**). Several observations were made. Firstly,
657 integrating multi-omics features, such as PRSs with PSCs/IDPs, enhanced predictions for
658 conditions like mental and behavioral disorders (ICD: F) and metabolic diseases (ICD: E),
659 specifically for brain PSCs and PRSs. Secondly, cross-organ imaging features demonstrated
660 greater predictive power than single-organ features, exemplified by improved predictions for
661 mental and behavioral disorders using brain PSCs and heart IDPs. Lastly, the best performance
662 was achieved by combining cross-organ imaging features and PRSs together, such as using brain
663 PSCs, eye IDPs, and their PRSs to predict mental and behavioral disorders (**Fig. 8a**).
664 Importantly, there was no evidence of overfitting when comparing the results obtained from the
665 nested CV test datasets (*CV accuracy*, shown in **Fig. 8a**) to those derived from the independent
666 test dataset (*Ind. accuracy*, detailed in **Supplementary eFile 56-58**). We refrained from
667 statistically comparing the classification performance between machine learning models due to
668 the complexities involved within a complex nested cross-validation setup⁸³ and the liberty in
669 standard statistical tests like a two-sample t-test. Instead, we present the mean and standard
670 deviation of the CV results. Notably, neural networks exhibited comparable results to support
671 vector machines in the independent test dataset (**Supplementary eFile 59** for brain and heart
672 features). **Supplementary eFigure 25** compares our brain PSCs with conventional atlas-based
673 brain IDPs (i.e., the MUSE ROIs), demonstrating data-driven PSCs with higher balanced
674 accuracy than MUSE ROIs in certain disease categories, especially for mental and behavioral
675 disorders.

676 Overall, the predictive capacity for predicting the 8 cognitive scores was low using the
677 2003 PSCs, 82 heart IDPs, 84 eye IDPs, and their derived PRSs regarding Pearson's r (<0.15).
678 When combining the features across the two organs, using support vector regression, the
679 prediction performance substantially increased for some cognitive scores, especially for fluid
680 intelligence and DSST. Brain PSCs achieved better prediction results for the tower rearranging
681 test than the other two organs (**Fig. 8b**). Additionally, integrating age and sex as supplementary
682 features notably improved the prediction performance (**Supplementary eFigure 26**). Detailed

683 metrics regarding the predictions using different features and machine learning models are
 684 shown in **Supplementary eFile 60-63**.

685
 686 **Figure 8: Prediction ability of the 2003 brain PSCs and 82 heart IDPs for predicting 14**
 687 **systemic diseases and 8 cognitive scores**



688
 689 **a)** The classification for the 14 ICD-based disease categories was assessed using brain, heart, and
 690 eye features and their respective PRSs via support vector machines in a nested cross-validation
 691 (CV) procedure (i.e., training/validation/test datasets). We present the balanced accuracy from
 692 the CV results. **b)** Cognition prediction was assessed via support vector regression using brain,
 693 heart, and eye features, as well as their respective PRSs. Pearson's r coefficient reflects the
 694 relationship between predicted values and the ground truth from the CV test datasets. Additional
 695 metrics, results using alternative machine learning methods, and outcomes from the independent
 696 test dataset can be found in **Supplementary eFile 56-58**. The size of the pie charts reflects the
 697 balanced accuracy achieved using specific feature sets. A more filled-in pie chart signifies higher
 698 accuracy.
 699

700 Discussion

701 This study established a comprehensive brain-heart-eye axis by integrating multi-omics and
702 multi-organ data from UKBB, BLSA, FinnGen, and PGC. We examined this axis across multiple
703 scales to reveal its intricate phenotypic landscape, proteomic map, and genetic architecture. Our
704 findings highlighted both within-organ specificity and cross-organ interactions among the three
705 organs, further dissecting the association toward causality in chronic diseases. Additionally, our
706 machine learning-based predictions underscored the importance of incorporating features from
707 multiple organs and omics data, promoting a multi-organ approach for modeling human aging
708 and disease.

709 **The phenotypic landscape of the brain-heart-eye axis highlights relevant imaging 710 biomarkers**

711 The brain-eye PWAS highlights the central visual pathway marked by distinct brain regions and
712 ocular features, providing insights into the underlying neurobiological basis and potential new
713 imaging biomarkers. The central visual pathway – linking the retina to the midbrain, thalamus,
714 and the primary visual cortex – represents an intricate neural network that establishes a critical
715 connection between the eye and the brain, orchestrating the transmission and processing of visual
716 information⁵². Our PWAS results emphasize the pivotal contribution of ganglion cells (GcpIR
717 and GcpIL of the eye IDPs) within the brain-eye nexus. These cells in the retina possess
718 extensive axons that project into the brain, forming the optic nerve. This initiates the primary
719 pathway for transmitting visual information from the eye to the brain, extending through the
720 retina, optic nerve, optic chiasm, and optic tract. The degeneration of retinal ganglion cells has
721 been associated with various ocular pathologies, encompassing glaucoma, hereditary optic
722 neuropathies, ischaemic optic neuropathies, and demyelinating diseases^{85,86}, as well as diseases
723 related to the CNS⁸⁷. The central visual pathway in the brain progresses to the thalamus's LGN
724 before reaching the occipital lobe's primary visual cortex. This progression is supported by the
725 distinct patterns observed in PSCs that spatially encompass these regions (closest-matching PSCs
726 for thalamus: <https://labs-laboratory.com/bridgeport/music/thalamus>). Prior research has probed
727 into glaucoma pathology, focusing on the retina and optic nerve heads, showcasing degenerative
728 brain alterations encompassing the intracranial optic nerve, lateral geniculate nucleus, and visual
729 cortex^{88,89}. Multiple MRI studies have also investigated the correlation between brain structure
730 alterations and eye conditions^{90,91}. For example, in patients with neurodegenerative conditions,
731 such as AD⁹²⁻⁹⁵, the eye serves as a portal to assess brain health.

732 The brain-heart PWAS emphasizes related brain areas, such as PSCs for deep subcortical
733 structures, the prefrontal and insular cortex, alongside heart features, such as the myocardial
734 mass and wall thickness of the left ventricle (LVM), and the end-diastolic volume of the right
735 ventricle (RVEDV). This supports the “neuro-cardiac axis⁹⁶”, which refers to the intricate
736 connection and communication pathways between the brain and the heart. This axis involves the
737 bidirectional interaction of neurological signals and cardiac responses, influencing each other's
738 function and regulation. It also encompasses various brain regions responsible for autonomic
739 nervous system control, emotional processing, and cognitive functions, which affect cardiac
740 activity, rhythm, and cardiovascular health. For example, the limbic system, including the
741 emotional coding center⁹⁷, amygdala (closest-matching PSCs: [https://labs-
742 laboratory.com/bridgeport/music/amygdala](https://labs-laboratory.com/bridgeport/music/amygdala)), and the cerebral cortex, contribute to autonomic
743 nervous system modulation, particularly in response to emotions, stress, and cognitive
744 processes⁹⁸. More broadly, the pathophysiological interplays of the nervous and cardiovascular
745

746 systems, evidenced by constant communication between the heart and the brain, have proved
747 invaluable to interdisciplinary fields of neurological and cardiac diseases^{49,99–101}. Consistent with
748 a previous study using conventional brain IDPs⁸, which highlighted numerous associations
749 between subcortical structures and global eye wall thickness, our PSC PWAS validates this
750 pattern, which reveals the most prominent brain PSC and heart IDP associations within
751 subcortical PSCs in a purely data-driven fashion.

752 In our PWAS analysis, the heart IDPs and eye IDPs showed weaker associations than the
753 other two pairs of organs. This can be attributed to several factors. First, the brain shows a strong
754 functional specialization to the other two organs. The brain has direct regulatory control over
755 both the heart and the eye through neural pathways. The central autonomic network, as
756 evidenced by our results, directly influences heart function, while the brain's visual processing
757 areas are closely linked to eye function. This direct control and specialization may lead to
758 stronger associations. Secondly, this also leads to the fact that physiological pathways connecting
759 the brain to the heart and eye are more direct than those connecting the heart and eye. Another
760 possibility is that many neurological conditions can manifest with both cardiovascular and ocular
761 symptoms, creating stronger brain-heart and brain-eye associations. However, a recent review¹⁰²
762 also highlighted that identifying retinal microvascular disease and retinal biomarkers could offer
763 valuable insights into the progression of microvascular disease in other systemic vascular regions
764 over time.

766 **The proteomics map of the brain-heart-eye axis depicts organ-specific and cross-organ** 767 **interconnections**

768 Our ProWAS offers additional evidence supporting the brain-heart-eye axis at the protein level.
769 We observed predominantly organ-specific protein expression profiles within individual organs,
770 while notable cross-organ interactions were also obvious. We further discuss the potential
771 implications of the ProWAS results by exemplifying significant proteins over-expressed in
772 tissues from respective organs.

773 In the brain ProWAS, the MOG protein, encoded by the *MOG* gene located on
774 chromosome 6p22.1 (**Supplementary eFigure 27a**), represents myelin oligodendrocyte
775 glycoprotein. This protein primarily facilitates homophilic cell-cell adhesion. As a minor
776 component of the myelin sheath, MOG plays a role in the completion and maintenance of the
777 myelin sheath and cell-cell communication. This protein was significantly linked to many PSCs,
778 including the C32_1 ($N=4235$; $\beta=89.88\pm 9.34$; $-\log_{10}(P\text{-value})=20.96$), encompassing the deep
779 subcortical structures (**Supplementary eFigure 27b**). For organ/tissue-specific expression
780 analysis, this protein showed high expression in several brain tissues and gastrointestinal tracts
781 like the small intestine (**Supplementary eFigure 27c**). To further depict specific brain regions
782 showing high expression of this protein, we calculated the normalized RNA expression levels
783 (nTPM) for 13 brain tissues. White matter tissue showed the highest nTPM (**Supplementary**
784 **eFigure 27d**). This aligns with our understanding that white matter is abundant in
785 oligodendrocytes, which are essential for myelination. Additionally, this protein is classified in
786 cluster 9, 'Oligodendrocytes – Myelination', according to protein expression clustering analysis
787 (**Supplementary eFigure 27e**), where it shows a high correlation with myelin basic protein
788 (MBP) ($r=0.9982$). Moreover, this protein also exhibits cell type-specific enrichment in
789 cardiomyocytes from heart muscle (**Supplementary eFigure 27f**). Cancer-type specific
790 enrichment showed 5.9 FPKM in glioma among 17 cancer types using RNA-seq data from the
791 TCGA dataset¹⁰³ (**Supplementary eFigure 27g**).

792 Another example is the PLTP (phospholipid transfer protein) protein (**Supplementary**
793 **eFigure 28a**), which was significantly linked to the average thickness of the INL/RPE layer
794 (InLRpeL: https://labs-laboratory.com/medicine/average_inlrpe_thickness_left_f28536_0_0), and
795 showed a high expression in various human tissues/organs, including the brain, eye, and heart
796 (**Supplementary eFigure 28b-c**). This protein mainly facilitates the transfer of phospholipids
797 and free cholesterol from triglyceride-rich lipoproteins (such as low-density lipoproteins or LDL
798 and very low-density lipoproteins or VLDL) into high-density lipoproteins and also enables the
799 exchange of phospholipids among triglyceride-rich lipoproteins. Tissue cell-type-specific
800 enrichment analysis revealed a significant presence of macrophages across various tissues
801 (**Supplementary eFigure 28d**), which plays a pivotal role in the innate immune response.
802 Single-cell type analysis in the retina showed substantial expression of this protein in a type of
803 retinal glial cells (Müller glial cell; **Supplementary eFigure 28e**). Our protein-level analyses
804 exemplify complex implications for the PLTP protein in specific retinal mechanisms. These
805 findings suggest potential links between PLTP function in the retina and its roles in other brain
806 regions and peripheral organs.

807 In the heart ProWAS, we highlight the TGFA (transforming growth factor alpha;
808 **Supplementary eFigure 29a**) protein, which showed a high expression in tissues from various
809 organs (**Supplementary eFigure 29b-c**). TGFA is a mitogenic polypeptide that exhibits binding
810 affinity for the epidermal growth factor receptor. TGFA demonstrates synergistic activity with
811 transforming growth factor beta (TGF- β) in promoting anchorage-independent cell proliferation.
812 The TGFA protein was significantly linked to multiple heart IDPs, such as the maximum volume
813 of the RA (RAV_max: [https://labs-](https://labs-laboratory.com/medicine/ra_maximum_volume_f24114_2_0)
814 [laboratory.com/medicine/ra_maximum_volume_f24114_2_0](https://labs-laboratory.com/medicine/ra_maximum_volume_f24114_2_0)). Regional brain expression
815 analysis revealed that white matter exhibited the highest enrichment of this protein, with an
816 nTPM value of 53.2 (**Supplementary eFigure. 29d**).

817 818 **Genetic evidence of the brain-heart-eye axis dissects causal relationships within a multi-** 819 **organ network**

820 Our GWAS and post-GWAS analyses provide comprehensive genetic evidence that may shape
821 this brain-heart-eye axis's observed phenotypic landscape and proteomics map.

822 Our GWAS uncovered shared genetic variants commonly associated with brain PSCs,
823 eye IDPs, and heart IDPs. These findings have several important implications and suggest
824 potential shared biological pathways. First, the joint associations between genetic variants and
825 imaging features across the brain, eye, and heart emphasize cross-organ pleiotropic effects¹⁰⁴.
826 Second, chronic diseases affecting these three organs might share similar pathological and
827 biological pathways. For instance, complex diseases like Alzheimer's, cardiovascular diseases,
828 and certain ocular conditions often have multifactorial causes. Identifying common genetic
829 variants helps elucidate the genetic contributions to these diseases and their effects on different
830 organs. Third, cross-organ causality may also contribute to the shared genetic variants, supported
831 by our Mendelian randomization and genetic colocalization analyses (**Fig. 7c-e**).

832 We calculated several key genetic parameters to depict the genetic architecture of the
833 three organs. We observed that SNP-based heritability estimates were higher for brain PSCs and
834 eye IDPs compared to heart IDPs, with a P-value of 0.10 when comparing brain PSCs to heart
835 IDPs and a P-value of 4.12×10^{-19} for eye IDPs versus heart IDPs. This aligns with our previous
836 study, where we assessed the heritability of biological age across the three organs using machine
837 learning techniques¹⁰. In that study, we examined the underlying factors contributing to this

838 phenomenon, such as allele frequency, sample sizes, and the quality of the imaging features. We
839 then compared the natural selection signature (S) and polygenicity (Pi) across the three organs.
840 Our results showed a widespread signature of negative selection of the three organs, with the eye
841 IDPs showing the largest magnitude (P-value<0.001) compared to the other two organs (**Fig. 5**
842 **d-f**). These findings are consistent with previous literature¹⁰⁵, where Zeng et al. found signatures
843 of negative selection in 28 human complex traits. The retina is a highly conserved structure
844 across different species, having been subject to significant purifying selection pressures to
845 preserve its essential role in vision. This strong selection pressure ensures the removal of
846 deleterious mutations, maintaining the retina's functional integrity over evolutionary time. For
847 instance, a prior multi-omics analysis study identified 178 ultrarare variants within 84
848 ultraconserved non-coding regions (UCRs) linked to 29 disease genes during retinal
849 development¹⁰⁶; the negative selective pressure on these regions is much stronger than on
850 protein-coding regions. In contrast, the brain's adaptability and plasticity allow it to meet diverse
851 functional demands, potentially reducing the selection pressure on specific brain traits. This
852 complexity often involves a myriad of genes with small individual effects, which can diffuse the
853 impact of purifying selection typically seen in traits with fewer (i.e., polygenicity), likely more
854 significant genetic determinants. Our polygenicity estimates support this, where the eye IDPs
855 obtained the lowest Pi estimates (P-value< 1×10^{-10} , **Fig. 5 g-i**).

856 The tissue-specific heritability enrichment results emphasize notable heritability
857 enrichment within organ-specific tissues (**Fig. 5j-l**). For example, the heritability enrichment of
858 ganglia, which also aggregates outside the brain – like those in the retina¹⁰⁷ and cardiac
859 ganglia¹⁰⁸ – offers cellular evidence supporting this inter-organ communication. Additionally, we
860 noticed a greater significance in the enrichment analyses (indicated by significant P-values)
861 when employing chromatin data compared to gene expression data. This observation aligns with
862 the original heritability enrichment analysis carried out by Finucane et al.¹⁰⁹, wherein the authors
863 identified more significant enrichment signals in chromatin data than gene expression data in
864 disease-relevant tissues and cell types. The genetic correlation between the PSCs/IDPs of each
865 pair of organs largely mirrors their phenotypic associations, supporting the long-standing
866 Cheverud's Conjecture⁷².

867 Finally, Mendelian randomization analyses established 6 causal networks between the
868 three organs (**Fig. 7f-h**). It highlighted potential causal relationships between imaging-derived
869 endophenotypes¹¹⁰ (PSCs/IDPs) and various chronic disease endpoints across different organs.
870 For example, we identified multiple heart IDPs that were causally linked to three brain diseases:
871 depression, migraine, and AD. In a previous study, Zhao et al. also found similar causal evidence
872 between psychiatric disorders and heart IDPs, but their analysis was limited to pre-selected, well-
873 powered traits from multiple publicly available resources. Our study extends previous
874 research^{8,58} by implementing bi-directional causal analysis across the brain, heart, and eye. This
875 approach revealed additional insights, including causal links between several heart IDPs and
876 ocular diseases, such as glaucoma.

877 878 **Multi-organ features improve prediction for systemic disease categories and cognition**

879 We demonstrated the clinical potential of these brain PSCs, heart and eye IDPs, and their
880 respective PRSs using machine learning for precision diagnostics. Notably, integrating multi-
881 scale data from different organs and omics enhanced predictive power.

882 Previous research has shown the great potential of these *in vivo* imaging biomarkers for
883 advancing precision medicine. However, one limitation of these machine learning methods

884 emerges from models trained solely on features derived from individual organ systems or omics
885 data. This approach might inadequately capture the multifaceted pathological effects of
886 underlying conditions, especially considering the co-occurring comorbidities across different
887 systems, such as the cardiovascular contributions for epilepsy¹¹¹ and dementia¹¹². Importantly,
888 while the individual impact of brain PSCs, heart IDPs, and their PRSs is limited in predicting
889 systemic disease categories and cognitive scores, their supplementary power beyond basic
890 demographics like age and sex, compared to features from a single organ, emphasizes the
891 necessity for a multi-organ approach in future research. Another challenge in applying machine
892 learning for precision medicine is the reproducibility crisis^{113,114}, as demonstrated in our prior
893 research on AD classification using convolutional neural networks²². Consequently, open
894 science, permitting the community to examine the model, source code, and reuse the GWAS
895 summary statistics, is crucial to advancing the field toward potential clinical translation. To
896 address this, we made all our resources and results publicly available at the MEDICINE
897 knowledge portal: <https://labs-laboratory.com/medicine/> and the BRIDGEPORT knowledge
898 portal: <https://labs-laboratory.com/bridgeport>.

899

900 **Integrating machine learning and artificial intelligence in multi-organ research**

901 Machine learning and artificial intelligence have been widely applied in biomedical research. For
902 example, the foundational model proposed by Zhou et al.³⁹ may potentially enhance its
903 capabilities by leveraging multi-organ imaging data during training. Recent studies^{115,9} focused
904 on determining the biological age of nine distinct human organ systems and identifying the
905 clinical and genetic factors that underlie the multifaceted aging process. These findings
906 underscore the clinical promise of utilizing these AI-derived endophenotypes to gauge and
907 understand the collective health of multiple organs. Machine learning and artificial intelligence
908 have gained significant attention due to several factors. First, they are adept at handling high-
909 dimensional biomedical data, such as brain MRI and genetics. They can distill the complex data
910 into lower-dimensional yet clinically rich imaging and genetic signatures. Second, these data-
911 driven models are considered more clinically and biologically relevant because they can capture
912 underlying neurobiological effects related to aging and diseases. Additionally, integrating
913 disease-related information from multiple modalities, such as imaging and genetics¹¹⁶, may
914 enhance the power of discoveries in subsequent genetic discoveries.

915

916 **Limitation**

917 Our study presents several limitations. Primarily, our genetic analysis concentrated solely on
918 common genetic variants, prompting future inquiries into the potential impact of rare variants
919 within this brain-heart-eye axis. Additionally, our GWAS analyses were predominantly based on
920 participants of European ancestry. Future research efforts should encompass underrepresented
921 racial and ethnic groups and disease-specific populations. Additionally, future research should
922 investigate the impact of environmental factors and gene-environment interactions on the
923 phenotypic variance of the three organs. Furthermore, the prevalence of missing proteomics data
924 presents significant challenges for implementing multivariate AI/ML approaches. Future
925 research will address this issue through improved data collection strategies and the development
926 of advanced imputation methodologies¹¹⁷ for missing data imputation. Finally, the multi-scale
927 brain PSCs across different scales are interconnected, even though our previous work¹
928 demonstrated that integrating cross-scale features enhances disease classification. Future

929 methodological advancements could focus on conditioning model training across scales to ensure
930 that the derived PSCs are more independent.

931

932 **Outlook**

933 In summary, this study integrates machine learning, imaging genetics, and proteomics to map the
934 brain-heart axis across multiple scales. We expect these findings to broaden future research
935 avenues, encouraging the adoption of machine learning techniques in multi-organ, multi-omics
936 studies for precision medicine.

937 **Methods**

938 **Method 1: The MULTI consortium**

939 The MULTI consortium is an ongoing initiative to integrate and consolidate multi-organ data,
940 such as brain and heart MRI and eye OCT, with multi-omics data at individual and summary
941 levels, including imaging, genetics, and proteomics. Building on existing consortia and studies,
942 such as those listed below, MULTI aims to curate and harmonize the data to model human aging
943 and disease across the lifespan.

945 **UK Biobank**

946 UKBB⁴² is a population-based research initiative comprising around 500,000 individuals
947 gathered from the United Kingdom between 2006 and 2010. Ethical approval for the UKBB
948 study has been secured, and information about the ethics committee can be found here:
949 [https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/governance/ethics-advisory-](https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/governance/ethics-advisory-committee)
950 [committee](https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/governance/ethics-advisory-committee).

951 This study collectively analyzed 39,567 brain MRI scans (referred to as the *brain*
952 *population*), 39,676 heart MRI scans (representing the *heart populations*, varying from 33,866 to
953 39,286 per specific IDP), and 64,316 eye OCT images (i.e., the *eye populations* varied from
954 15,997 to 61,732 per IDP) at baseline. The combined sample size across the three organ
955 populations totaled 104,509. The T1-weighted MRI data underwent processing at the University
956 of Pennsylvania, employing the MuSIC atlas to produce the 2003 brain PSCs¹. Concurrently, the
957 82 heart IDPs were obtained directly from the UKBB website and derived from a prior study²
958 (Category ID: 157). Meanwhile, the 84 eye IDPs, derived from OCT imaging, were directly
959 downloaded from the UKBB website and returned by previous studies³⁻⁵ (Category ID: 100079).
960 The sample sizes employed in the brain-heart PWAS, exploring overlapping populations
961 between brain PSCs and heart IDPs, ranged from 21,948 to 23,548 individuals, depending on the
962 analyzed features. Of note, the brain and heart MRIs were scanned at the same visit/session. The
963 sample sizes for the overlapping populations between the brain PSCs and eye IDPs used in
964 PWAS varied from 1284 to 4472 individuals. The small sample sizes were because the brain
965 MRI and eye OCT were scanned at different time/session points. For comprehensive
966 information, including the complete list of phenotypes and their respective sample sizes, refer to
967 **Supplementary eTable 1**.

968 For the genetic data, we conducted a quality check on the imputed genotype data⁴² for the
969 entire UKBB population (approximately ~500k individuals). Subsequently, we merged the
970 processed data with the *eye & heart population* for genetic analyses; the genetic quality check
971 was performed on the brain population for the brain PSCs, as indicated in our previous study¹.
972 Refer to **Method 5** for details. Our primary focus was on populations of European ancestry, with
973 non-European ancestry populations included in sensitivity check analyses. The preprocessing for
974 the proteomics data is detailed below.

975

976 **Baltimore Longitudinal Study of Aging**

977 BLSA^{45,54} data (<https://www.blsa.nih.gov/>) were used to replicate the brain ProWAS results from
978 the UKBB study. We finally included measurements of 7268 plasma proteins from 924
979 participants quantified with the SomaScan v4.1 platform after quality checks and merging with
980 the imaging populations. Age (years), sex (male/female), race (white/non-white), and education
981 level (years) were defined based on participant self-reports.

982

983 **FinnGen**

984 The FinnGen⁴⁶ study investigates combined genetic information alongside health registry data to
985 unravel the origins and mechanisms behind various disease endpoints. Its primary emphasis lies
986 in understanding the genetic foundations of diseases prevalent in the Finnish population,
987 surpassing 500,000 individuals. This is accomplished through extensive GWAS and thorough
988 analysis of vast genomic data in collaboration with multiple research entities. For the benefit of
989 research, FinnGen generously made their GWAS findings accessible to the wider scientific
990 community (https://www.finngen.fi/en/access_results). This research utilized the publicly
991 released GWAS summary statistics (version R9), which became available on May 11, 2022, after
992 harmonization by the consortium. No individual data were used in the current study.

993 FinnGen published the R9 version of GWAS summary statistics via REGENIE software
994 (v2.2.4)¹¹⁸, covering 2272 disease endpoints, including 2269 binary traits and 3 quantitative
995 traits. The GWAS model encompassed covariates like age, sex, the initial 10 genetic principal
996 components, and the genotyping batch. Genotype imputation was referenced on the population-
997 specific SISu v4.0 panel. Specifically, we included GWAS summary statistics for 45 heart, 32
998 eye diseases, and 41 brain diseases in our analyses.

999

1000 **Psychiatric Genomics Consortium**

1001 PGC⁴⁷ is an international collaboration of researchers studying the genetic basis of psychiatric
1002 disorders. PGC aims to identify and understand the genetic factors contributing to various
1003 psychiatric disorders such as schizophrenia, bipolar disorder, major depressive disorder, and
1004 others. The GWAS summary statistics were acquired from the PGC website
1005 (<https://pgc.unc.edu/for-researchers/download-results/>), underwent quality checks, and were
1006 harmonized to ensure seamless integration into our analysis. No individual data were used from
1007 PGC. Each study detailed its specific GWAS models and methodologies, and the consortium
1008 consolidated the release of GWAS summary statistics derived from individual studies. In the
1009 current study, we included 4 brain diseases.

1010

1011 **Method 2: Imaging analyses**

1012 **(a) Patterns of structural covariance of the brain:** Our earlier work¹ applied the sopNMF
1013 method to a large-scale cohort of brain MRIs ($N=50,699$). This resulted in 2003 multi-scale brain
1014 PSCs, wherein the scale C ranged from 32 to 1024, expanding exponentially by a factor of 2. Of
1015 note, 13 PSCs from $C1024$ vanished during modeling, resulting in 2003 PSCs.

1016 PSCs represent data-driven structural networks that encapsulate coordinated
1017 neuroanatomical changes in brain morphology stemming from a mixture of normal aging,
1018 pathology, and unmodeled factors, such as environmental and genetic influences.
1019 Mathematically, the sopNMF algorithm is a deep learning-like stochastic approximation
1020 constructed and extended based on opNMF^{44,119}. Consider a dataset comprising n MR images,
1021 each containing d voxels. The imaging data are represented as a matrix \mathbf{X} , where each column
1022 corresponds to a flattened image: $\mathbf{X} = [x_1, x_2, \dots, x_n]$, $\mathbf{X} \in \mathbb{R}_{\geq 0}^{d \times n}$. The sopNMF algorithm
1023 factorizes \mathbf{X} into two low-rank matrices $\mathbf{W} \in \mathbb{R}_{\geq 0}^{d \times r}$ and $\mathbf{H} \in \mathbb{R}_{\geq 0}^{r \times n}$, subject to the constraints of
1024 *i*) non-negativity and *ii*) column-wise orthonormality. More mathematical details are presented in
1025 **Supplementary eMethod 2** and the original references^{1,44,119}.

1026

1027 **(b) Imaging-derived phenotypes of the heart:** The 82 heart IDPs were directly downloaded
1028 from the UKBB website (Category ID: 157). Bai et al.² studied a broad spectrum of structural
1029 and functional characteristics for the heart and aorta, measured through heart MRI data sourced
1030 from UKBB, employing an automated analysis pipeline based on machine learning. They
1031 investigated the correlations of these heart IDPs with factors such as sex, age, key cardiovascular
1032 risk elements, and other non-imaging traits. As demonstrated in our present study, this
1033 exploration unveils new research avenues for scrutinizing disease mechanisms and developing
1034 image-based biomarkers across diverse organ systems assessed through advanced imaging
1035 techniques. For the 82 heart IDPs included in our analyses, we further categorized them into 6
1036 different IDP groups for visualization purposes, as shown in **Supplementary eTable 1**.

1037
1038 **(c) Imaging-derived phenotypes of the eye:** For the 88 eye IDPs, we downloaded the derived
1039 OCT measurements from the UKBB website (Category ID: 100079) and used the imaging
1040 quality scores (Field ID: 28552 and 28553) for quality check. We excluded 12,044 individuals
1041 whose scores were lower than 45 (Category ID: 100116). Additionally, we restricted our analysis
1042 to IDPs with sample sizes surpassing 10,000 within the European ancestry, excluding four IDPs.

1043 OCT imaging is an advanced, non-invasive technology that generates three-dimensional
1044 images of the macula, crucial for detailed central vision. Abnormalities in macular thickness and
1045 morphology captured by OCT imaging are sensitive biomarkers of diabetic retinopathy, age-
1046 related macular degeneration, glaucoma, sleeping, and various neurodegenerative diseases^{120,121}.
1047 Three prior studies³⁻⁵ processed the OCT images to derive the 84 eye IDPs used in our analyses,
1048 and the results were subsequently returned to UKBB, making them accessible to the community.
1049 Ko et al.⁴ and Patel et al.³ from the UKBB Eyes and Vision Consortium
1050 (<https://www.ukbiobankeyeconsortium.org.uk/>; Return code: 1873 and 1875) analyzed OCT
1051 images from over 60,000 individuals in the UKBB. They derived variables related to the
1052 thickness of the retinal pigment epithelium (excluding outliers and individuals with diseases
1053 affecting macular thickness). They associated the thickness measures with age, myopia,
1054 ethnicity, smoking, and intraocular pressure. A subsequent investigation by Han et al.⁵ extracted
1055 optic nerve head morphology measures and performed a GWAS on these additional eye IDPs.
1056 For the 84 eye IDPs included in our analyses, we further categorized them into 11 different IDP
1057 groups for visualization purposes (**Supplementary eTable 1**).

1058 1059 **Method 3: Phenome-wide associations between the three organs**

1060 **(a) Primary PWAS:** We performed three sets of primary PWAS that correlated *i*) the 2003 brain
1061 PSCs with the 82 heart IDPs, *ii*) the 2003 brain PSCs with the 84 eye IDPs, and *iii*) the 84 eye
1062 IDPs and 82 heart IDPs, employing a linear regression model where each organ-specific feature
1063 served as the dependent variable while the other functioned as the independent variable.

1064 For the brain-heart PWAS, we accounted for various covariates, including age (Field ID:
1065 21003), sex (Field ID: 31), brain positioning in the scanner (lateral, transverse, and longitudinal;
1066 Field ID: 25756-25758), head motion (Field ID: 25741), intracranial volume, body weight (Field
1067 ID: 21002), height (Field ID: 50), waist circumference (Field ID: 48), BMI (Field ID: 23104),
1068 smoking status (Field ID: 20116), diastolic (Field ID: 4079), and systolic (Field ID: 4080) blood
1069 pressure, assessment center (Field ID: 54), body surface area (Field ID: 22427), average heart
1070 rate (Field ID: 22426), along with the first 40 genetic principal components. For the brain-eye
1071 PWAS, we controlled for age (Field ID:21003 for both brain and eye assessment), sex (Field ID:
1072 31), brain position in the scanner (lateral, transverse, and longitudinal; Field ID: 25756-25758),

1073 head motion (Field ID: 25741), intracranial volume, body weight (Field ID: 21002 for both brain
1074 and eye assessment), height (Field ID: 50 for both brain and eye assessment), waist
1075 circumference (Field ID: 48 for both brain and eye assessment), and first 40 genetic principal
1076 components as covariates. For the heart-eye PWAS, we included covariates for age (Field
1077 ID:21003 for both heart and eye assessment), sex (Field ID: 31), body weight (Field ID: 21002
1078 for both heart and eye assessment), height (Field ID: 50 for both heart and eye assessment), waist
1079 circumference (Field ID: 48 for both heart and eye assessment), and first 40 genetic principal
1080 components, smoking status (Field ID: 20116), diastolic (Field ID: 4079), and systolic (Field ID:
1081 4080) blood pressure, assessment center (Field ID: 54), and BMI (Field ID: 23104).

1082 We conducted two sensitivity analyses to check the robustness of our main PWAS: *i*)
1083 sex-specific PWAS for males and females and *ii*) split-sample PWAS by randomly dividing the
1084 entire population into two groups, ensuring that there were no significant differences in sex and
1085 age between the two splits.

1086
1087 **(b) Secondary PWAS:** A secondary PWAS was conducted to link the brain PSCs, heart, and eye
1088 IDPs with other 117 phenotypes (excluding the heart and eye IDPs used here) accessible in our
1089 downloaded UK Biobank database (**Supplementary eFile 4 and 5**). The same linear regression
1090 model mentioned above was used. We explicitly excluded the multimodal brain IDPs²⁶
1091 (Category code: 100) from this PWAS to prevent circular bias with our brain PSCs¹²².

1092 1093 **Method 4: Proteome-wide associations of the brain PSCs, heart, and eye IDPs**

1094 **(a) Proteome-wide associations:** We performed three sets of ProWAS that correlated *i*) the
1095 2003 brain PSCs, *ii*) the 82 heart IDPs, and *iii*) 84 eye IDPs with 2923 unique proteins
1096 (10,018< N <39,489) using the Olink platform. The original data were analyzed and made
1097 available to the community by the UK Biobank Pharma Proteomics Project. The initial quality
1098 check was detailed in the original work⁴⁸; we performed additional quality check steps as below.
1099 We focused our analysis on the first instance of the proteomics data ("instance"=0).
1100 Subsequently, we merged the Olink files containing coding information, batch numbers, assay
1101 details, and limit of detection (LOD) data (Category ID: 1839) to match the ID of the proteomics
1102 dataset. We eliminated Normalized Protein eXpression (NPX) values below the protein-specific
1103 LOD. Furthermore, we restricted our analysis to proteins with sample sizes exceeding 10,000. Of
1104 note, we observed a high prevalence of missing values across individuals for the 2923 proteins,
1105 posing challenges for employing multivariate machine learning models.

1106 For the brain ProWAS, we accounted for various covariates, including age (Field ID:
1107 21003), sex (Field ID: 31), brain positioning in the scanner (lateral, transverse, and longitudinal;
1108 Field ID: 25756-25758), head motion (Field ID: 25741), intracranial volume, body weight (Field
1109 ID: 21002), height (Field ID: 50), waist circumference (Field ID: 48), BMI (Field ID: 23104),
1110 assessment center (Field ID: 54), protein batch number (Category ID: 1839), limit of detection
1111 (LOD; Category ID: 1839), along with the first 40 genetic principal components. For the eye
1112 ProWAS, we controlled for age (Field ID:21003 for eye assessment instance), sex (Field ID: 31),
1113 body weight (Field ID: 21002 for eye assessment), height (Field ID: 50 for eye assessment),
1114 waist circumference (Field ID: 48 for eye assessment), protein batch number (Category ID:
1115 1839), limit of detection (LOD; Category ID: 1839), and first 40 genetic principal components as
1116 covariates. For the heart ProWAS, we included covariates for age (Field ID:21003), sex (Field
1117 ID: 31), body weight (Field ID: 21002), height (Field ID: 50), waist circumference (Field ID:
1118 48), and first 40 genetic principal components, smoking status (Field ID: 20116), diastolic (Field

1119 ID: 4079), systolic (Field ID: 4080) blood pressure, assessment center (Field ID: 54), and BMI
1120 (Field ID: 23104), protein batch number (Category ID: 1839), and LOD (Category ID: 1839).
1121 Multiple comparisons were performed using Bonferroni corrections based on the number of
1122 proteins and the number of PSC or IDP for each organ. We also used the time interval as an
1123 alternative covariate in the model for image data from organs that were not collected at the same
1124 visit as the proteomics data.

1125
1126 **(b) Tissue/organ-specific map of the expression of the human proteome:** To integrate our
1127 ProWAS results within the framework of multi-organ connections, we annotated the
1128 tissue/organ-specific expression patterns of significant proteins using the Human Protein
1129 Atlas¹²³. This integrated the RNA and protein level data from multiple sources, including the
1130 HPA, GTEX¹²⁴, and FANTOM5¹²⁵ datasets, to comprehensively assess tissue "over-expression"
1131 profiles for the significant proteins. The protein data encompasses 15,303 genes for which
1132 antibodies are available. The RNA expression data is obtained from deep sequencing of RNA
1133 (RNA-seq) across different tissue types. The methodology determining the expression of the
1134 protein is detailed in the original publication¹²³. Importantly, proteins are then simultaneously
1135 over-expressed in various tissues or organs (i.e., lack of organ-specificity). Our main objective
1136 was to determine if the tested protein exhibited expression in the brain, eye, and heart. If it was
1137 not over-expressed in any of these three organs, we highlighted its expression in other tissues
1138 with the highest evidence of over-expression.

1139 1140 **Method 5: Genetic analyses**

1141 We used the imputed genotype data for all genetic analyses, and our quality check pipeline
1142 resulted in 33,541 participants (8,469,833 SNPs passing quality check) for the *brain population*,
1143 33,743 participants (6,477,810 SNPs passing quality check) for the *heart population*, and 48,016
1144 participants (6,477,810 SNPs passing quality check) for the *eye population* with European
1145 ancestry. We summarize our genetic quality check steps. First, we excluded related individuals
1146 (up to 2nd-degree) from the full UKBB sample using the KING software for family relationship
1147 inference.¹²⁶ Importantly, in the GWAS for heart and eye IDPs using fastGWA⁵⁷, we skipped
1148 this step, as the linear mixed model inherently addresses population stratification, encompassing
1149 additional cryptic population stratification factors. We then removed duplicated variants from all
1150 22 autosomal chromosomes. Individuals whose genetically identified sex did not match their
1151 self-acknowledged sex were removed. Other excluding criteria were: *i*) individuals with more
1152 than 3% of missing genotypes; *ii*) variants with minor allele frequency (MAF) of less than 1%;
1153 *iii*) variants with larger than 3% missing genotyping rate; *iv*) variants that failed the Hardy-
1154 Weinberg test at 1×10^{-10} . To adjust for population stratification,¹²⁷ we derived the first 40 genetic
1155 principle components using the FlashPCA software¹²⁸. Details of the genetic quality check
1156 protocol are described elsewhere^{1,9,10,129}. The quality check for the brain PSC GWAS was
1157 conducted within the brain imaging genetic populations¹, whereas the heart and eye IDP GWAS
1158 was carried out across the entire 500k UKBB population, leading to the different numbers of
1159 valid SNPs.

1160 1161 **(a) GWAS:**

1162 **Brain PSC GWAS:** In our prior study¹, we performed linear regression using Plink¹³⁰ for each
1163 brain PSC within a subset of the UKBB brain population (discovery set; $N=18,052$; European
1164 ancestry). Following this, we replicated the findings in another dataset (replication set);

1165 $N=15,243$). This study presents GWASs from the combined discovery and replication sets
1166 ($N=33,541$ European ancestry). The brain PSC GWAS controlled for confounding factors,
1167 including age (Field ID:21003), age-squared, sex (Field ID:31), age x sex interaction, age-
1168 squared x sex interaction, the first 40 genetic principal components, and total intracranial
1169 volume, guided by earlier brain imaging GWASs^{26,61}. We employed a stringent genome-wide P-
1170 value threshold ($5 \times 10^{-8}/2003$) using Bonferroni correction based on the number of PSCs
1171 ($N=2003$) to ensure stringent statistical rigor.

1172
1173 **Heart IDP GWAS:** We applied a linear mixed model regression to the European ancestry
1174 populations using fastGWA⁵⁷ implemented in GCTA⁶⁰. The model included age (Field ID:
1175 21003), age-squared, sex (Field ID: 31), age x sex interaction, age-squared x sex interaction, the
1176 first 40 genetic principal components, body weight (Field ID: 21002), height (Field ID: 50), and
1177 waist circumference (Field ID: 48), BMI (Field ID: 23104), smoking status (Field ID: 20116),
1178 assessment center (Field ID: 54), heart rate (Field ID: 12673), diastolic (Field ID: 12675), and
1179 systolic (Field ID: 12674) blood pressure, peripheral pulse pressure (Field ID: 12676), central
1180 pulse pressure (Field ID: 12678), body surface area (Field ID: 22427), average heart rate (Field
1181 ID: 22426), as covariates. Likewise, based on the number of heart IDPs, we applied the
1182 Bonferroni correction on top of the genome-wide significant threshold ($5 \times 10^{-8}/82$).

1183
1184 **Eye IDP GWAS:** We applied a linear mixed model regression to the European ancestry
1185 populations using fastGWA⁵⁷ ($12,120 < N < 45,897$ across the 84 eye IDPs). The model included
1186 age (Field ID: 21003), age-squared, sex (Field ID: 31), age x sex interaction, age-squared x sex
1187 interaction, the first 40 genetic principal components, body weight (Field ID: 21002), height
1188 (Field ID: 50), and waist circumference (Field ID: 48) as covariates. Similarly, based on the
1189 number of eye IDPs, we applied the Bonferroni correction on top of the genome-wide significant
1190 threshold ($5 \times 10^{-8}/84$).

1191 We scrutinized the robustness of the brain PSC GWAS in our previous study¹. Here, we
1192 assessed the reliability of our heart and eye IDP GWAS results through several sensitivity
1193 analyses. These checks included: *i*) a split-sample GWAS that randomly divided the entire heart
1194 population into two groups with no significant differences in sex and age, *ii*) sex-stratified
1195 GWAS conducted separately for males and females, *iii*) a non-European GWAS to gauge the
1196 generalizability of GWAS signals identified in populations of European ancestry, *iv*) PLINK
1197 linear model GWAS to compare genetic signals with fastGWA, and *v*) validation against the
1198 prior heart and eye IDP GWAS by Zhao et al.^{8,58}, which used data from UKBB with different
1199 sample sizes and valid SNP after quality check.

1200
1201 **Annotation of genomic loci:** For heart and eye IDP GWASs, genomic loci were annotated using
1202 FUMA¹³¹. For genomic loci annotation, FUMA initially identified lead SNPs (correlation $r^2 \leq$
1203 0.1, distance < 250 kilobases) and assigned them to non-overlapping genomic loci. The lead SNP
1204 with the lowest P-value (i.e., the top lead SNP) represented the genomic locus. Further details on
1205 the definitions of top lead SNP, lead SNP, independent significant SNP, and candidate SNP can
1206 be found in **Supplementary eMethod 1**. To identify genomic loci in the brain PSC GWAS, we
1207 utilized PLINK with parameters for clumping that matched those of the FUMA online platform.
1208 This choice was made due to the resource constraints of the FUMA platform in handling tasks at
1209 this scale ($N=2003$), as described in our prior study¹.

1210

1211 **(b) PheWAS:** We used the GWAS Atlas⁵⁹ platform to conduct an online PheWAS look-up
1212 analysis for the top lead SNP within each genomic locus; linkage disequilibrium was fully
1213 considered in this case. To facilitate this, we developed an "in-house web crawler" designed to
1214 automate searches on the PheWAS webpage: <https://atlas.ctglab.nl/PheWAS>. The search
1215 threshold was set at a P-value of 5×10^{-8} . The GWAS Atlas PheWAS categorized these traits into
1216 different broad domains/categories. This PheWAS was conducted on December 2, 2023.

1217
1218 **(c) SNP-based heritability:** We calculated the SNP-based heritability (h^2) using the GCTA
1219 software, which employs raw individual genotype data to generate a genetic relationship matrix,
1220 addressing the "missing heritability" issue⁶⁰. Additionally, we estimated h^2 using the LDSC⁵⁶
1221 software, leveraging only GWAS summary statistics derived from our brain PSC, heart, and eye
1222 IDP GWASs as an alternative approach. To this end, we used precomputed LD scores from the
1223 European ancestry in the 1000 Genomes dataset. Notably, disparities in SNP-based h^2 estimates
1224 were observed between the two software tools, which is in line with our own findings^{10,12} and
1225 those from other studies^{26,61}. Consequently, we present the GCTA estimates in the main
1226 manuscript and the LDSC estimates in the supplement. Bonferroni correction based on the
1227 number of PSCs/IDPs was applied to denote statistical significance.

1228
1229 **(d) Selection signature and polygenicity estimate:** We used SBayesS⁶³ to estimate two sets of
1230 parameters that unveil the genetic architecture of the PSCs and IDPs. SBayesS is an expanded
1231 approach capable of estimating essential parameters characterizing the genetic architecture of
1232 complex traits through a Bayesian mixed linear model¹⁰⁵. This method only requires GWAS
1233 summary statistics of the SNPs and LD information from a reference sample. These parameters
1234 include polygenicity (P_i), and the relationship between minor allele frequency (MAF) and effect
1235 size (S). We used the software pre-computed sparse LD correlation matrix derived from the
1236 European ancestry by Zeng et al.⁶³. More mathematical details can be found in the original paper
1237 from Zeng et al.⁶³. We ran the *gctb* command¹⁰⁵ using the argument `--sbayes S`, and left all other
1238 arguments by default.

1239
1240 **(e) Tissue-specific partitioned heritability estimate:** This analysis aims to comprehend the
1241 varying roles of distinct tissue types in contributing to the heritability of the brain PSCs and heart
1242 and eye IDPs. To achieve this, the partitioned heritability analysis through stratified LD score
1243 regression assesses the extent of heritability enrichment attributed to predefined and annotated
1244 genome regions and categories⁶⁴. This analysis considers two sets of analyses considering
1245 different tissue types: *i*) 498 multi-tissue chromatin-based annotations from peaks from six
1246 epigenetic marks using data from ROADMAP⁶⁶ and ENTE⁶⁷ and *ii*) 205 multi-tissue gene
1247 expression data estimate using data from GTEx V8⁶⁵ and "Franke lab" dataset. Bonferroni
1248 correction is applied to all tested annotations and categories (0.05/498/205). Detailed
1249 methodologies for the stratified LD score regression are outlined in the original work⁶⁴. LD
1250 scores and allele frequencies for European ancestry were acquired from a predefined version
1251 based on data from the 1000 Genomes project.

1252
1253 **(f) Gene-drug-disease network:** We defined a gene-drug-disease network by examining the
1254 enrichment of the significant genes linked to the 2003 brain PSCs, 82 heart IDPs, and 84 eye
1255 IDPs within specific drug categories from the DrugBank database⁶⁹ using the GREP software⁶⁸.
1256 First, the gene-level association test was performed using MAGMA¹³². Then, gene annotation

1257 was performed to map the SNPs (reference variant location from Phase 3 of 1,000 Genomes for
1258 European ancestry) to genes according to their physical positions. We then performed gene-level
1259 associations based on the SNP GWAS summary statistics to obtain gene-level P-values to define
1260 the Bonferroni-corrected significant genes linked to each PSC/IDP (P-value<0.05/18,761). Using
1261 these significant genes as input, GREP conducted Fisher's exact tests to determine whether these
1262 genes were enriched in gene sets targeted by drugs within clinical indication categories for
1263 specific diseases or conditions (based on the ICD code). FDR correction was applied to account
1264 for multiple tests to signify significant gene-drug-disease relationships.
1265

1266 **(g) Genetic correlation:** We estimated the genetic correlation (g_c) between each PSC-IDP pair
1267 utilizing the LDSC software. Precomputed LD scores from the 1000 Genomes of European
1268 ancestry were employed, maintaining default settings for other parameters in LDSC. It's worth
1269 noting that LDSC corrects for sample overlap, ensuring an unbiased genetic correlation
1270 estimate¹³³. Statistical significance was determined using Bonferroni correction, considering the
1271 number of PSCs or IDPs ($N=2003, 84, \text{ or } 82$, whichever is the largest).
1272

1273 **(h) Bayesian colocalization:** We explored the genetic colocalization signals between pairwise
1274 PSC-IDP and IDP-IDP at each genomic locus defined by respective GWASs using the *coloc*
1275 package. Specifically, we employed the Fully Bayesian colocalization analysis⁷³ utilizing Bayes
1276 Factors (*coloc.abf*). This method assesses the posterior probability (PP.H4.ABF: Approximate
1277 Bayes Factor) to evaluate hypothesis H4, indicating the presence of a single shared causal variant
1278 associated with both traits. To establish the significance of the H4 hypothesis, a threshold of
1279 PP.H4.ABF>0.8⁷³ was set. All other parameters, such as the prior probability of p_{12} , were
1280 maintained at their default values.
1281

1282 **(i) Two-sample bidirectional Mendelian randomization:** We postulated that the brain PSCs
1283 and heart and eye IDPs, acting as intermediate phenotypes (endophenotypes)¹³⁴, might have
1284 causal connections to chronic disease endpoints across the three organs. To test this hypothesis,
1285 we constructed six bi-directional causal networks: *i) Brain2Heart, ii) Heart2Brain, iii)*
1286 *Brain2Eye, iv) Eye2Brain, v) Heart2Eye, and vi) Eye2Heart*. These networks used GWAS
1287 summary statistics from our analyses in the UKBB, the FinnGen⁴⁶, and the PGC⁴⁷ study for the
1288 brain, heart, and eye disease endpoints. The *Brain2Heart* causal network employed the 2003
1289 brain PSCs from UKBB as exposure variables and the 45 heart diseases from FinnGen (R9) as
1290 outcome variables (disease code: I9). The *Heart2Brain* network investigated causality from the
1291 82 heart IDPs from UKBB as exposure variables to 41 FinnGen brain diseases (disease code: F5
1292 and G6) as outcome variables. The *Brain2Eye* causal network utilizes the 2003 brain PSCs from
1293 UKBB as exposure variables and the 32 eye diseases from FinnGen (R9) as outcome variables
1294 (disease code: H7). The *Eye2Brain* network explores causality from the 84 eye IDPs from
1295 UKBB as exposure variables to 41 FinnGen brain diseases as outcome variables (disease code:
1296 F5 and G6). Regarding significant signals related to brain diseases, we employed the GWAS
1297 summary statistics of 4 brain diseases from the PGC to replicate the signals independently (i.e.,
1298 AD). Finally, The *Heart2Eye* network investigated causality from the 82 heart IDPs from UKBB
1299 as exposure variables to 41 brain diseases (disease code: F5 and G6) from FinnGen as outcome
1300 variables. The *Eye2Heart* network explored causality from the 84 eye IDPs from UKBB as
1301 exposure variables to 45 heart diseases (disease code: I9) from FinnGen as outcome variables.

1302 The systematic quality-checking procedures to ensure unbiased exposure/outcome variable and
1303 instrumental variable (IVs) selection are detailed below.

1304 We used a two-sample Mendelian randomization approach implemented in the
1305 *TwoSampleMR* package⁸⁰ to infer the causal relationships within the two networks. We
1306 employed five distinct Mendelian randomization methods, presenting the results of the inverse
1307 variance weighted (IVW) method in the main text and the outcomes of the other four methods
1308 (Egger, weighted median, simple mode, and weighted mode estimators) in the supplement. The
1309 STROBE-MR Statement¹³⁵ guided our analyses to increase transparency and reproducibility,
1310 encompassing the selection of exposure and outcome variables, reporting statistics, and
1311 implementing sensitivity checks to identify potential violations of underlying assumptions. First,
1312 we performed an unbiased quality check on the GWAS summary statistics. Notably, the absence
1313 of population overlapping bias¹³⁶ was confirmed, given that FinnGen and UKBB participants
1314 largely represent populations of European ancestry without explicit overlap; PGC GWAS
1315 summary data were ensured to exclude UKBB participants. Furthermore, all consortia's GWAS
1316 summary statistics were based on or lifted to GRCh37. Subsequently, we selected the effective
1317 exposure variables by assessing the statistical power of the exposure GWAS summary statistics
1318 in terms of instrumental variables (IVs), ensuring that the number of IVs exceeded 8 before
1319 harmonizing the data. Crucially, the function "*clump_data*" was applied to the exposure GWAS
1320 data, considering linkage disequilibrium. The function "*harmonise_data*" was then used to
1321 harmonize the GWAS summary statistics of the exposure and outcome variables. This yielded
1322 varying numbers of brain PSCs, heart IDPsm, and eye IDPs as effective exposure variables for
1323 the abovementioned six causal networks. Bonferroni correction was applied to all tested traits
1324 based on the number of effective PSC/IDPs or diseases, whichever was larger.

1325 Finally, we conducted multiple sensitivity analyses. Initially, we conducted a
1326 heterogeneity test to scrutinize potential violations in the IV's assumptions. To assess horizontal
1327 pleiotropy, which indicates the IV's exclusivity assumption¹³⁷, we utilized a funnel plot, single-
1328 SNP Mendelian randomization methods, and the Egger estimator. Furthermore, we performed a
1329 leave-one-out analysis, systematically excluding one instrument (SNP/IV) at a time, to gauge the
1330 sensitivity of the results to individual SNPs.

1331
1332 **(j) PRS calculation:** The PRS was computed using split-sample sensitivity GWASs for the heart
1333 and eye IDP-PRSs and discovery/replication GWASs for the brain PSCs. The PRS weights were
1334 established using split1/discovery GWAS data as the base/training set, while the
1335 split2/replication GWAS summary statistics served as the target/testing data. Both base and
1336 target data underwent rigorous quality control procedures involving several steps: *i*) excluding
1337 duplicated and ambiguous SNPs in the base data; *ii*) performing clumping of the base GWAS
1338 data; *iii*) pruning to remove highly correlated SNPs in the target data; *iv*) excluding high
1339 heterozygosity samples in the target data; and *v*) eliminating duplicated, mismatching, and
1340 ambiguous SNPs in the target data.

1341 After completing the QC procedures, PRS for the split2 group was calculated using
1342 PLINK and the conventional C+T method (clumping + thresholding). To identify the most
1343 suitable PRS, we performed a linear regression considering various P-value thresholds (0.001,
1344 0.05, 0.1, 0.2, 0.3, 0.4, 0.5), while accounting for age, sex, intracranial volume (if applicable),
1345 and the forty genetic principal components. The optimal P-value threshold for each brain PSC-
1346 PRS and heart IDP-PRS was determined based on achieving the highest incremental R^2 . We also
1347 explored the PRS-CS¹³⁹ method as an alternative to derive the PRSs and compared its prediction

1348 power with the PLINK C+T approach. Overall, PRS-CS obtained a higher incremental R^2 than
1349 PLINK but was less generalizable to other domains (i.e., the 14 disease categories), as detailed in
1350 **Supplementary eText 8**.

1351

1352 **Method 6: Disease and cognition prediction**

1353 We evaluated the predictive performance of the 2003 brain PSCs, 82 heart IDPs, 84 eye IDPs,
1354 and their respective PRSs in predicting 14 systemic disease categories and 8 cognitive scores.
1355 Patient cohorts for the 14 disease categories were identified using the ICD-10 code accessible on
1356 the UKBB website (Data field: 41270 and 41202). The healthy control group consisted of
1357 participants without any ICD-10-based disease diagnoses. **Supplementary eTable 2** details the
1358 14 ICD-10 disease categories and 8 cognitive scores.

1359

1360 **(a) Pseudo R-squared (R^2) statistics for individual feature-level prediction ability:** We used
1361 logistic regression to determine the incremental R^2 of the 2003 brain PSCs, 82 heart, and 84 eye
1362 IDPs, and their respective PRSs for predicting 14 disease categories individually. The null model
1363 included age, sex, and disease status as the outcome variable, while the alternative model
1364 introduced the PSC/IDP or their corresponding PRS as an additional predictor. The incremental
1365 R^2 was calculated as the difference between the pseudo R^2 of the alternative model and that of the
1366 null model, employing the *PseudoR2* function from the *DescTools* R package (v 0.99.38).
1367 Detailed results, including other metrics like sample sizes, P-values, and β coefficients, are
1368 presented in the supplementary data.

1369

1370 **(b) Systemic diseases classification:** We evaluated the predictive capabilities of six distinct
1371 feature sets for each pair of organs, such as brain PSC, heart IDP, brain PSC + PSC-PRS, heart
1372 IDP + IDP-PRS, brain PSC + heart IDP, and brain PSC + PSC-PRS + heart IDP + IDP-PRS,
1373 using a support vector machine and a nested CV procedure. This approach involved CV
1374 training/validation/test datasets and separate independent test datasets to assess performance. We
1375 showed the nested CV test balanced accuracy (*CV accuracy*), which addresses sample
1376 imbalance. The nested CV procedure included an outer loop of 10-fold CV, allocating 80% for
1377 training/validation and 20% for testing. Within each iteration, an inner loop used 80% of the
1378 training/validation data for a 10-fold training/validation split to tune hyperparameters. Alongside
1379 the nested CV datasets, we reserved 250 patients and 250 healthy controls for independent test
1380 datasets (*Ind. accuracy*), whenever feasible, considering sample sizes. Combining features from
1381 different organs (e.g., brain and heart) often led to reduced sample sizes, precluding the use of
1382 independent test datasets in some tasks. Supplementary data include additional metrics (e.g.,
1383 accuracy and sample sizes for the test data) for both test datasets. Additionally, the classification
1384 performance using neural networks (a five-layer fully connected network, nested CV was not
1385 applied) is detailed in supplementary data.

1386

1387 **(c) Cognitive scores regression:** Utilizing a similar nested CV approach, we employed the 6
1388 feature sets from different organs to predict 8 cognitive scores (**Supplementary eTable 2**) using
1389 support vector regression and lasso regression. We used Pearson's r as the main assessment
1390 metric derived from the training/validation/test datasets. Given the larger cognitive data sample
1391 sizes compared to classification tasks, we randomly sampled 1500 participants for the nested CV
1392 training/validation/test and left all other data as independent test datasets when applicable.

1393 Supplementary data provide additional metrics, such as mean absolute error, P-values, and
1394 detailed sample sizes.

1395 **Data Availability**

1396 The GWAS summary statistics corresponding to this study are publicly available on the
1397 MEDICINE knowledge portal (<https://labs-laboratory.com/medicine/>) and the BRIDGEPORT
1398 knowledge portal (<https://labs-laboratory.com/bridgeport>). Our study used data generated by the
1399 TCGA Research Network (<https://www.cancer.gov/tcga>), the human protein atlas (HPA:
1400 <https://www.proteinatlas.org>), and the STRING data (<https://string-db.org/>). The two platforms
1401 curated and consolidated publicly available (single-cell) RNA-seq and protein data, including the
1402 GTEx project (<https://gtexportal.org/home/>). Genomic loci annotation used data from FUMA
1403 (<https://fuma.ctglab.nl/>). PheWAS used data from the GWAS Atlas platform
1404 (<https://atlas.ctglab.nl/PheWAS>). GWAS summary data for the DEs were downloaded from the
1405 official websites of FinnGen (R9: https://www.finnngen.fi/en/access_results) and PGC
1406 (<https://pgc.unc.edu/for-researchers/download-results/>). Individual data from UKBB can be
1407 requested with proper registration at <https://www.ukbiobank.ac.uk/>. The gene-drug-disease
1408 network used data from the DrugBank database (v.5.1.9; <https://go.drugbank.com/>). The analysis
1409 for partitioned heritability estimates used data from ROADMAP
1410 (https://egg2.wustl.edu/roadmap/web_portal/) and ENTEEx (<https://www.encodeproject.org/>). All
1411 unrestricted data supporting the findings are also available from the corresponding author upon
1412 request.

1413 **Code Availability**

1414 The software and resources used in this study are all publicly available:

- 1415 • MLNI: <https://github.com/anbai106/mlni>, disease classification
- 1416 • PLINK: <https://www.cog-genomics.org/plink/>, linear model GWAS, PRS
- 1417 • FUMA: <https://fuma.ctglab.nl/>, gene mapping, genomic locus annotation
- 1418 • GCTA: <https://yanglab.westlake.edu.cn/software/gcta/#Overview>, heritability estimates,
1419 and fastGWA
- 1420 • LDSC: <https://github.com/bulik/ldsc>, genetic correlation, and heritability estimates
- 1421 • TwoSampleMR: <https://mrcieu.github.io/TwoSampleMR/index.html>, MR
- 1422 • Coloc: <https://chr1swallace.github.io/coloc/>, Bayesian colocalization
- 1423 • PRS-CS: <https://github.com/getian107/PRScs>, PRS

1424 **Competing Interests**

1425 None

1426

1427 **Authors' contributions**

1428 Dr. Wen has full access to all the data in the study and takes responsibility for the integrity of the
1429 data and the accuracy of the data analysis.

1430 *Study concept and design:* W.J

1431 *Acquisition, analysis, or interpretation of data:* W.J

1432 *Drafting of the manuscript:* W.J

1433 *Critical revision of the manuscript for important intellectual content:* All authors

1434 *Statistical analysis:* W.J with the help of B.P.A and D.M

1435 **References**

- 1436 1. Wen, J. *et al.* Genomic loci influence patterns of structural covariance in the human brain.
1437 *Proceedings of the National Academy of Sciences* **120**, e2300842120 (2023).
- 1438 2. Bai, W. *et al.* A population-based phenome-wide association study of cardiac and aortic
1439 structure and function. *Nat Med* **26**, 1654–1662 (2020).
- 1440 3. Patel, P. J. *et al.* Spectral-Domain Optical Coherence Tomography Imaging in 67 321
1441 Adults: Associations with Macular Thickness in the UK Biobank Study. *Ophthalmology*
1442 **123**, 829–840 (2016).
- 1443 4. Ko, F. *et al.* Associations with Retinal Pigment Epithelium Thickness Measures in a Large
1444 Cohort: Results from the UK Biobank. *Ophthalmology* **124**, 105–117 (2017).
- 1445 5. Han, X. *et al.* Genome-wide association analysis of 95 549 individuals identifies novel
1446 loci and genes influencing optic disc morphology. *Human Molecular Genetics* **28**, 3680–
1447 3690 (2019).
- 1448 6. Armour, J. A. Anatomy and Function of the Intrathoracic Neurons Regulating the
1449 Mammalian Heart. in *Reflex Control of the Circulation* (CRC Press, 1991).
- 1450 7. Conroy, G. This is the largest map of the human brain ever made. *Nature* **622**, 679–680
1451 (2023).
- 1452 8. Zhao, B. *et al.* Heart-brain connections: Phenotypic and genetic insights from magnetic
1453 resonance images. *Science* **380**, abn6598 (2023).
- 1454 9. Wen, J. *et al.* The genetic architecture of multimodal human brain age. *Nat Commun* **15**,
1455 2604 (2024).
- 1456 10. Wen, J. *et al.* The genetic architecture of biological age in nine human organ systems. *Nat*
1457 *Aging* 1–18 (2024) doi:10.1038/s43587-024-00662-8.

- 1458 11. McCracken, C. *et al.* Multi-organ imaging demonstrates the heart-brain-liver axis in UK
1459 Biobank participants. *Nat Commun* **13**, 7839 (2022).
- 1460 12. Wen, J. *et al.* Neuroimaging-AI Endophenotypes of Brain Diseases in the General
1461 Population: Towards a Dimensional System of Vulnerability. 2023.08.16.23294179
1462 Preprint at <https://doi.org/10.1101/2023.08.16.23294179> (2023).
- 1463 13. Nie, C. *et al.* Distinct biological ages of organs and systems identified from a multi-omics
1464 study. *Cell Reports* **38**, 110459 (2022).
- 1465 14. Liu, Y. *et al.* Genetic architecture of 11 organ traits derived from abdominal MRI using
1466 deep learning. *eLife* **10**, e65554 (2021).
- 1467 15. Oh, H. S.-H. *et al.* Organ aging signatures in the plasma proteome track health and disease.
1468 *Nature* **624**, 164–172 (2023).
- 1469 16. Jaggi, A. *et al.* A structural heart-brain axis mediates the association between
1470 cardiovascular risk and cognitive function. *Imaging Neuroscience* **2**, 1–18 (2024).
- 1471 17. Wen, J. Multiorgan biological age shows that no organ system is an island. *Nat Aging* 1–2
1472 (2024) doi:10.1038/s43587-024-00690-4.
- 1473 18. Hodson, R. Precision medicine. *Nature* **537**, S49–S49 (2016).
- 1474 19. Shen, L. & Thompson, P. M. Brain Imaging Genomics: Integrated Analysis and Machine
1475 Learning. *Proceedings of the IEEE* **108**, 125–162 (2020).
- 1476 20. Kendler, K. & Neale, M. Endophenotype: a conceptual analysis. *Mol Psychiatry* **15**, 789–
1477 797 (2010).
- 1478 21. Vandereyken, K., Sifrim, A., Thienpont, B. & Voet, T. Methods and applications for single-
1479 cell and spatial multi-omics. *Nat Rev Genet* **24**, 494–515 (2023).

- 1480 22. Wen, J. *et al.* Convolutional neural networks for classification of Alzheimer’s disease:
1481 Overview and reproducible evaluation. *Medical Image Analysis* **63**, 101694 (2020).
- 1482 23. Rotstein, D. & Montalban, X. Reaching an evidence-based prognosis for personalized
1483 treatment of multiple sclerosis. *Nat Rev Neurol* **15**, 287–300 (2019).
- 1484 24. Wen, J. *et al.* Subtyping Brain Diseases from Imaging Data. in *Machine Learning for Brain*
1485 *Disorders* (ed. Colliot, O.) 491–510 (Springer US, New York, NY, 2023). doi:10.1007/978-
1486 1-0716-3195-9_16.
- 1487 25. Yang, Z. *et al.* Brain aging patterns in a large and diverse cohort of 49,482 individuals. *Nat*
1488 *Med* 1–12 (2024) doi:10.1038/s41591-024-03144-x.
- 1489 26. Elliott, L. T. *et al.* Genome-wide association studies of brain imaging phenotypes in UK
1490 Biobank. *Nature* **562**, 210–216 (2018).
- 1491 27. Smith, S. M. *et al.* An expanded set of genome-wide association studies of brain imaging
1492 phenotypes in UK Biobank. *Nat Neurosci* **24**, 737–745 (2021).
- 1493 28. Zhao, B. *et al.* Common genetic variation influencing human white matter microstructure.
1494 *Science* **372**, (2021).
- 1495 29. Grasby, K. L. *et al.* The genetic architecture of the human cerebral cortex. *Science* **367**,
1496 eaay6690 (2020).
- 1497 30. Dewey, M. *et al.* Clinical quantitative cardiac imaging for the assessment of myocardial
1498 ischaemia. *Nat Rev Cardiol* **17**, 427–450 (2020).
- 1499 31. Petersen, S. E. *et al.* Reference ranges for cardiac structure and function using
1500 cardiovascular magnetic resonance (CMR) in Caucasians from the UK Biobank population
1501 cohort. *J Cardiovasc Magn Reson* **19**, 18 (2017).

- 1502 32. Biasioli, L. *et al.* Automated localization and quality control of the aorta in cine CMR can
1503 significantly accelerate processing of the UK Biobank population data. *PLoS One* **14**,
1504 e0212272 (2019).
- 1505 33. Ferdian, E. *et al.* Fully Automated Myocardial Strain Estimation from Cardiovascular MRI-
1506 tagged Images Using a Deep Learning Framework in the UK Biobank. *Radiol*
1507 *Cardiothorac Imaging* **2**, e190032 (2020).
- 1508 34. Bard, A. *et al.* Automated Quality-Controlled Cardiovascular Magnetic Resonance
1509 Pericardial Fat Quantification Using a Convolutional Neural Network in the UK Biobank.
1510 *Front Cardiovasc Med* **8**, 677574 (2021).
- 1511 35. Pirruccello, J. P. *et al.* Analysis of cardiac magnetic resonance imaging in 36,000
1512 individuals yields genetic insights into dilated cardiomyopathy. *Nat Commun* **11**, 2254
1513 (2020).
- 1514 36. Gomes, B. *et al.* Genetic architecture of cardiac dynamic flow volumes. *Nat Genet* 1–13
1515 (2023) doi:10.1038/s41588-023-01587-5.
- 1516 37. Aung, N. *et al.* Genome-wide association analysis reveals insights into the genetic
1517 architecture of right ventricular structure and function. *Nat Genet* **54**, 783–791 (2022).
- 1518 38. Levin, M. G. *et al.* Genome-wide association and multi-trait analyses characterize the
1519 common genetic architecture of heart failure. *Nat Commun* **13**, 6914 (2022).
- 1520 39. Zhou, Y. *et al.* A foundation model for generalizable disease detection from retinal images.
1521 *Nature* 1–8 (2023) doi:10.1038/s41586-023-06555-x.
- 1522 40. Ahadi, S. *et al.* Longitudinal fundus imaging and its genome-wide association analysis
1523 provide evidence for a human retinal aging clock. *Elife* **12**, e82364 (2023).

- 1524 41. Currant, H. *et al.* Genetic variation affects morphological retinal phenotypes extracted from
1525 UK Biobank optical coherence tomography images. *PLoS Genet* **17**, e1009497 (2021).
- 1526 42. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.
1527 *Nature* **562**, 203–209 (2018).
- 1528 43. Patel, K. *et al.* Unsupervised deep representation learning enables phenotype discovery for
1529 genetic association studies of brain imaging. *Commun Biol* **7**, 1–14 (2024).
- 1530 44. Sotiras, A., Resnick, S. M. & Davatzikos, C. Finding imaging patterns of structural
1531 covariance via Non-Negative Matrix Factorization. *NeuroImage* **108**, 1–16 (2015).
- 1532 45. Normal Human Aging: The Baltimore Longitudinal Study of Aging. *Journal of*
1533 *Gerontology* **40**, 767 (1985).
- 1534 46. Kurki, M. I. *et al.* FinnGen provides genetic insights from a well-phenotyped isolated
1535 population. *Nature* **613**, 508–518 (2023).
- 1536 47. O’Donovan, M. C. What have we learned from the Psychiatric Genomics Consortium.
1537 *World Psychiatry* **14**, 291–293 (2015).
- 1538 48. Sun, B. B. *et al.* Plasma proteomic associations with genetics and health in the UK
1539 Biobank. *Nature* **622**, 329–338 (2023).
- 1540 49. Silvani, A., Calandra-Buonaura, G., Dampney, R. A. L. & Cortelli, P. Brain–heart
1541 interactions: physiology and clinical implications. *Philosophical Transactions of the Royal*
1542 *Society A: Mathematical, Physical and Engineering Sciences* **374**, 20150181 (2016).
- 1543 50. Cudeiro, J. & Sillito, A. M. Looking back: corticothalamic feedback and early visual
1544 processing. *Trends in Neurosciences* **29**, 298–306 (2006).
- 1545 51. Sernagor, E., Eglén, S. J. & Wong, R. O. L. Development of Retinal Ganglion Cell
1546 Structure and Function. *Progress in Retinal and Eye Research* **20**, 139–174 (2001).

- 1547 52. Purves, D. *et al.* Central Visual Pathways. in *Neuroscience. 2nd edition* (Sinauer
1548 Associates, 2001).
- 1549 53. Doshi, J. *et al.* MUSE: MUlti-atlas region Segmentation utilizing Ensembles of registration
1550 algorithms and parameters, and locally optimal atlas selection. *Neuroimage* **127**, 186–195
1551 (2016).
- 1552 54. Duggan, M. R. *et al.* Proteomic analyses reveal plasma EFEMP1 and CXCL12 as
1553 biomarkers and determinants of neurodegeneration. *Alzheimers Dement* (2024)
1554 doi:10.1002/alz.14142.
- 1555 55. Szklarczyk, D. *et al.* The STRING database in 2023: protein-protein association networks
1556 and functional enrichment analyses for any sequenced genome of interest. *Nucleic Acids*
1557 *Res* **51**, D638–D646 (2023).
- 1558 56. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from
1559 polygenicity in genome-wide association studies. *Nat Genet* **47**, 291–295 (2015).
- 1560 57. Jiang, L. *et al.* A resource-efficient tool for mixed model association analysis of large-scale
1561 data. *Nat Genet* **51**, 1749–1755 (2019).
- 1562 58. Zhao, B. *et al.* Eye-brain connections revealed by multimodal retinal and brain imaging
1563 genetics. *Nat Commun* **15**, 6064 (2024).
- 1564 59. Watanabe, K. *et al.* A global overview of pleiotropy and genetic architecture in complex
1565 traits. *Nat Genet* **51**, 1339–1348 (2019).
- 1566 60. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: A Tool for Genome-wide
1567 Complex Trait Analysis. *Am J Hum Genet* **88**, 76–82 (2011).

- 1568 61. Zhao, B. *et al.* Genome-wide association analysis of 19,629 individuals identifies variants
1569 influencing regional brain volumes and refines their genetic co-architecture with cognitive
1570 and mental health traits. *Nat Genet* **51**, 1637–1644 (2019).
- 1571 62. Srivastava, A. K., Williams, S. M. & Zhang, G. Heritability Estimation Approaches
1572 Utilizing Genome-Wide Data. *Curr Protoc* **3**, e734 (2023).
- 1573 63. Zeng, J. *et al.* Widespread signatures of natural selection across human complex traits and
1574 functional genomic categories. *Nat Commun* **12**, 1164 (2021).
- 1575 64. Finucane, H. K. *et al.* Partitioning heritability by functional annotation using genome-wide
1576 association summary statistics. *Nat Genet* **47**, 1228–1235 (2015).
- 1577 65. The Genotype-Tissue Expression (GTEx) project. *Nat Genet* **45**, 580–585 (2013).
- 1578 66. Bernstein, B. E. *et al.* The NIH Roadmap Epigenomics Mapping Consortium. *Nat*
1579 *Biotechnol* **28**, 1045–1048 (2010).
- 1580 67. Dunham, I. *et al.* An integrated encyclopedia of DNA elements in the human genome.
1581 *Nature* **489**, 57–74 (2012).
- 1582 68. Sakaue, S. & Okada, Y. GREP: genome for REPositioning drugs. *Bioinformatics* **35**, 3821–
1583 3823 (2019).
- 1584 69. Wishart, D. S. *et al.* DrugBank 5.0: a major update to the DrugBank database for 2018.
1585 *Nucleic Acids Res* **46**, D1074–D1082 (2018).
- 1586 70. Nelson, M. R. *et al.* The support of human genetic evidence for approved drug indications.
1587 *Nat Genet* **47**, 856–860 (2015).
- 1588 71. Minikel, E. V., Painter, J. L., Dong, C. C. & Nelson, M. R. Refining the impact of genetic
1589 evidence on clinical success. *Nature* **629**, 624–629 (2024).

- 1590 72. Cheverud, J. M. A comparison of genetic and phenotypic correlations. *Evolution* **42**, 958–
1591 968 (1988).
- 1592 73. Giambartolomei, C. *et al.* Bayesian Test for Colocalisation between Pairs of Genetic
1593 Association Studies Using Summary Statistics. *PLOS Genetics* **10**, e1004383 (2014).
- 1594 74. Buniello, A. *et al.* The NHGRI-EBI GWAS Catalog of published genome-wide association
1595 studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res* **47**, D1005–D1012
1596 (2019).
- 1597 75. Gao, X. R., Huang, H. & Kim, H. Genome-wide association analyses identify 139 loci
1598 associated with macular thickness in the UK Biobank cohort. *Hum Mol Genet* **28**, 1162–
1599 1172 (2019).
- 1600 76. Bonelli, R. *et al.* Identification of genetic factors influencing metabolic dysregulation and
1601 retinal support for MacTel, a retinal disorder. *Commun Biol* **4**, 1–14 (2021).
- 1602 77. van der Meer, D. *et al.* Understanding the genetic determinants of the brain with MOSTest.
1603 *Nat Commun* **11**, 3512 (2020).
- 1604 78. Huang, J. *et al.* Genomics and phenomics of body mass index reveals a complex disease
1605 network. *Nat Commun* **13**, 7973 (2022).
- 1606 79. Giri, A. *et al.* Trans-ethnic association study of blood pressure determinants in over
1607 750,000 individuals. *Nat Genet* **51**, 51–62 (2019).
- 1608 80. Hemani, G. *et al.* The MR-Base platform supports systematic causal inference across the
1609 human phenome. *eLife* **7**, e34408 (2018).
- 1610 81. Wightman, D. P. *et al.* A genome-wide association study with 1,126,563 individuals
1611 identifies new risk loci for Alzheimer’s disease. *Nat Genet* **53**, 1276–1282 (2021).

- 1612 82. Lin, S. *et al.* Inferring the genetic relationship between brain imaging-derived phenotypes
1613 and risk of complex diseases by Mendelian randomization and genome-wide colocalization.
1614 *NeuroImage* **279**, 120325 (2023).
- 1615 83. Nadeau, C. & Bengio, Y. Inference for the Generalization Error. *Machine Learning* **52**,
1616 239–281 (2003).
- 1617 84. Curcio, C. A. & Allen, K. A. Topography of ganglion cells in human retina. *Journal of*
1618 *Comparative Neurology* **300**, 5–25 (1990).
- 1619 85. Khatib, T. Z. & Martin, K. R. Protecting retinal ganglion cells. *Eye* **31**, 218–224 (2017).
- 1620 86. Smith, C. A., Vianna, J. R. & Chauhan, B. C. Assessing retinal ganglion cell damage. *Eye*
1621 **31**, 209–217 (2017).
- 1622 87. Marchesi, N., Fahmideh, F., Boschi, F., Pascale, A. & Barbieri, A. Ocular
1623 Neurodegenerative Diseases: Interconnection between Retina and Cortical Areas. *Cells* **10**,
1624 2394 (2021).
- 1625 88. Gupta, N., Ang, L., de Tilly, L. N., Bidaisee, L. & Yücel, Y. H. Human glaucoma and
1626 neural degeneration in intracranial optic nerve, lateral geniculate nucleus, and visual cortex.
1627 *Br J Ophthalmol* **90**, 674–678 (2006).
- 1628 89. Gupta, N. & Yücel, Y. H. Brain changes in glaucoma. *Eur J Ophthalmol* **13 Suppl 3**, S32-
1629 35 (2003).
- 1630 90. Prins, D., Hanekamp, S. & Cornelissen, F. W. Structural brain MRI studies in eye diseases:
1631 are they clinically relevant? A review of current findings. *Acta Ophthalmol* **94**, 113–121
1632 (2016).

- 1633 91. Brown, H. D. H., Woodall, R. L., Kitching, R. E., Baseler, H. A. & Morland, A. B. Using
1634 magnetic resonance imaging to assess visual deficits: a review. *Ophthalmic Physiol Opt* **36**,
1635 240–265 (2016).
- 1636 92. Sen, S., Saxena, R., Tripathi, M., Vibha, D. & Dhiman, R. Neurodegeneration in
1637 Alzheimer’s disease and glaucoma: overlaps and missing links. *Eye* **34**, 1546–1553 (2020).
- 1638 93. Blanks, J. C., Hinton, D. R., Sadun, A. A. & Miller, C. A. Retinal ganglion cell
1639 degeneration in Alzheimer’s disease. *Brain Res* **501**, 364–372 (1989).
- 1640 94. Whittaker, K. W., Burdon, M. A. & Shah, P. Visual field loss and Alzheimer’s disease. *Eye*
1641 **16**, 206–208 (2002).
- 1642 95. Shah, T. M., Gupta, S. M., Chatterjee, P., Campbell, M. & Martins, R. N. Beta-amyloid
1643 sequelae in the eye: a critical review on its diagnostic significance and clinical relevance in
1644 Alzheimer’s disease. *Mol Psychiatry* **22**, 353–363 (2017).
- 1645 96. Prasad Hrishi, A., Ruby Lionel, K. & Prathapadas, U. Head Rules Over the Heart: Cardiac
1646 Manifestations of Cerebral Disorders. *Indian J Crit Care Med* **23**, 329–335 (2019).
- 1647 97. Miller, M. Emotional Rescue: The Heart–Brain Connection. *Cerebrum* **2019**, cer-05-19
1648 (2019).
- 1649 98. Mulkey, S. B. & du Plessis, A. J. Autonomic Nervous System Development and its’ Impact
1650 on Neuropsychiatric Outcome. *Pediatr Res* **85**, 120–126 (2019).
- 1651 99. Chen, Z. *et al.* Brain–Heart Interaction. *Circulation Research* **121**, 451–468 (2017).
- 1652 100. Vaccarino, V. *et al.* Brain-heart connections in stress and cardiovascular disease:
1653 Implications for the cardiac patient. *Atherosclerosis* **328**, 74–82 (2021).
- 1654 101. Daemen, M. J. A. P. The heart and the brain: an intimate and underestimated relation. *Neth*
1655 *Heart J* **21**, 53–54 (2013).

- 1656 102. Chew, E. Y. *et al.* Standardization and clinical applications of retinal imaging biomarkers
1657 for cardiovascular disease: a Roadmap from an NHLBI workshop. *Nat Rev Cardiol* 1–17
1658 (2024) doi:10.1038/s41569-024-01060-8.
- 1659 103. Weinstein, J. N. *et al.* The Cancer Genome Atlas Pan-Cancer Analysis Project. *Nat Genet*
1660 **45**, 1113–1120 (2013).
- 1661 104. Stearns, F. W. One Hundred Years of Pleiotropy: A Retrospective. *Genetics* **186**, 767–773
1662 (2010).
- 1663 105. Zeng, J. *et al.* Signatures of negative selection in the genetic architecture of human complex
1664 traits. *Nat Genet* **50**, 746–753 (2018).
- 1665 106. Lopez Soriano, V. *et al.* Multi-omics analysis in human retina uncovers ultraconserved cis-
1666 regulatory elements at rare eye disease loci. *Nat Commun* **15**, 1600 (2024).
- 1667 107. Hahn, J. *et al.* Evolution of neuronal cell classes and types in the vertebrate retina. *Nature*
1668 **624**, 415–424 (2023).
- 1669 108. Veerakumar, A., Yung, A. R., Liu, Y. & Krasnow, M. A. Molecularly defined circuits for
1670 cardiovascular and cardiopulmonary control. *Nature* **606**, 739–746 (2022).
- 1671 109. Finucane, H. K. *et al.* Heritability enrichment of specifically expressed genes identifies
1672 disease-relevant tissues and cell types. *Nat Genet* **50**, 621–629 (2018).
- 1673 110. Wen, J. *et al.* MUTATE: A Human Genetic Atlas of Multi-organ AI Endophenotypes using
1674 GWAS Summary Statistics. 2024.06.15.24308980 Preprint at
1675 <https://doi.org/10.1101/2024.06.15.24308980> (2024).
- 1676 111. Romoli, M. & Costa, C. Cardiovascular risk factors for epilepsy and dementia. *Nat Rev*
1677 *Neurol* **19**, 391–392 (2023).

- 1678 112. Qiu, C. & Fratiglioni, L. A major role for cardiovascular burden in age-related cognitive
1679 decline. *Nat Rev Cardiol* **12**, 267–277 (2015).
- 1680 113. Stoddart, C. Is there a reproducibility crisis in science? *Nature* (2016) doi:10.1038/d41586-
1681 019-00067-3.
- 1682 114. Adam, D. What reproducibility crisis? New research protocol yields ultra-high replication
1683 rate. *Nature* **623**, 467–468 (2023).
- 1684 115. Tian, Y. E. *et al.* Heterogeneous aging across multiple organ systems and prediction of
1685 chronic disease and mortality. *Nat Med* 1–11 (2023) doi:10.1038/s41591-023-02296-6.
- 1686 116. Yang, Z. *et al.* Gene-SGAN: discovering disease subtypes with imaging and genetic
1687 signatures via multi-view weakly-supervised deep clustering. *Nat Commun* **15**, 354 (2024).
- 1688 117. An, U. *et al.* Deep learning-based phenotype imputation on population-scale biobank data
1689 increases genetic discoveries. *Nat Genet* **55**, 2269–2276 (2023).
- 1690 118. Mbatchou, J. *et al.* Computationally efficient whole-genome regression for quantitative and
1691 binary traits. *Nat Genet* **53**, 1097–1103 (2021).
- 1692 119. Zhirong Yang & Oja, E. Linear and Nonlinear Projective Nonnegative Matrix
1693 Factorization. *IEEE Trans. Neural Netw.* **21**, 734–749 (2010).
- 1694 120. Stretton, B., Kovoov, J. G., Bacchi, S. & Chan, W. O. A common factor? Sleep, macular
1695 degeneration and neurodegenerative disease. *Eye* 1–1 (2023) doi:10.1038/s41433-023-
1696 02607-8.
- 1697 121. Zhou, M., Li, D.-L., Kai, J.-Y., Zhang, X.-F. & Pan, C.-W. Sleep duration and the risk of
1698 major eye disorders: a systematic review and meta-analysis. *Eye* **37**, 2707–2715 (2023).
- 1699 122. Kriegeskorte, N., Simmons, W. K., Bellgowan, P. S. F. & Baker, C. I. Circular analysis in
1700 systems neuroscience: the dangers of double dipping. *Nat. Neurosci.* **12**, 535–540 (2009).

- 1701 123. Uhlén, M. *et al.* Tissue-based map of the human proteome. *Science* **347**, 1260419 (2015).
- 1702 124. Ratnapriya, R. *et al.* Retinal transcriptome and eQTL analyses identify genes associated
1703 with age-related macular degeneration. *Nat Genet* **51**, 606–610 (2019).
- 1704 125. Takahashi, H., Lassmann, T., Murata, M. & Carninci, P. 5' end-centered expression
1705 profiling using cap-analysis gene expression and next-generation sequencing. *Nat Protoc* **7**,
1706 542–561 (2012).
- 1707 126. Manichaikul, A. *et al.* Robust relationship inference in genome-wide association studies.
1708 *Bioinformatics* **26**, 2867–2873 (2010).
- 1709 127. Price, A. L., Zaitlen, N. A., Reich, D. & Patterson, N. New approaches to population
1710 stratification in genome-wide association studies. *Nat Rev Genet* **11**, 459–463 (2010).
- 1711 128. Abraham, G., Qiu, Y. & Inouye, M. FlashPCA2: principal component analysis of Biobank-
1712 scale genotype datasets. *Bioinformatics* **33**, 2776–2778 (2017).
- 1713 129. Wen, J. *et al.* Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical
1714 Symptoms, and Genetics Among Patients With Late-Life Depression. *JAMA Psychiatry*
1715 (2022) doi:10.1001/jamapsychiatry.2022.0020.
- 1716 130. Purcell, S. *et al.* PLINK: A Tool Set for Whole-Genome Association and Population-Based
1717 Linkage Analyses. *Am J Hum Genet* **81**, 559–575 (2007).
- 1718 131. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and
1719 annotation of genetic associations with FUMA. *Nat Commun* **8**, 1826 (2017).
- 1720 132. Leeuw, C. A. de, Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: Generalized Gene-
1721 Set Analysis of GWAS Data. *PLOS Computational Biology* **11**, e1004219 (2015).
- 1722 133. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits.
1723 *Nat Genet* **47**, 1236–1241 (2015).

- 1724 134. Gottesman, I. I. & Gould, T. D. The endophenotype concept in psychiatry: etymology and
1725 strategic intentions. *Am J Psychiatry* **160**, 636–645 (2003).
- 1726 135. Skrivankova, V. W. *et al.* Strengthening the Reporting of Observational Studies in
1727 Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. *JAMA* **326**,
1728 1614–1621 (2021).
- 1729 136. Sanderson, E. *et al.* Mendelian randomization. *Nat Rev Methods Primers* **2**, 1–21 (2022).
- 1730 137. Bowden, J. *et al.* A framework for the investigation of pleiotropy in two-sample summary
1731 data Mendelian randomization. *Stat Med* **36**, 1783–1802 (2017).
- 1732 138. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid
1733 instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol*
1734 **44**, 512–525 (2015).
- 1735 139. Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C. A. & Smoller, J. W. Polygenic prediction via
1736 Bayesian regression and continuous shrinkage priors. *Nat Commun* **10**, 1776 (2019).
- 1737
- 1738
- 1739

1740 **Acknowledgments**

1741 The MULTI consortium (J.W) aims to integrate multi-organ imaging with multi-omics data to
1742 advance our understanding of human aging and disease mechanisms. We want to express our
1743 sincere gratitude to the UK Biobank team for their invaluable contribution to advancing clinical
1744 research in our field (<https://www.ukbiobank.ac.uk/>). We also acknowledge the data sharing
1745 from the UKBB Eye and Vision Consortium ([https://www.ukbiobank.ac.uk/enable-your-
1746 research/approved-research/genetic-contribution-to-vision-loss-and-disability-the-uk-biobank-
1747 eye-vision-consortium](https://www.ukbiobank.ac.uk/enable-your-research/approved-research/genetic-contribution-to-vision-loss-and-disability-the-uk-biobank-eye-vision-consortium); Return ID: 1875) and UKB-PPP consortium
1748 (<https://registry.opendata.aws/ukbPPP/>; Category code: 1838) to share the returned data with the
1749 community. We thank FinnGen (<https://www.finnngen.fi/en>) and PGC (<https://pgc.unc.edu/>) for
1750 their generosity in sharing the GWAS summary statistics with the scientific community. We
1751 thank the BLSA participants and staff for their participation and continued dedication. The
1752 BLSA protocol was approved by the Institutional Review Board of the National Institute of
1753 Environmental Health Science, National Institutes of Health (03AG0325). This study used the
1754 UK Biobank resource under Application Number 35148 (D.C) under the NIH-funded
1755 iSTAGING consortium (D.C; grant number: RF1 AG054409). We thank Dr. Wenjia Bai for
1756 generously providing us access to the cardiac atlas utilized in his publication:
1757 <https://wp.doc.ic.ac.uk/wbai/data/>. We acknowledge the leadership of the Brain Imaging
1758 Genetics (BIG) workgroup, led by Dr. Tavia Evans, Dr. Natalia Vilor-Tejedor, and Dr. Junhao
1759 Wen, within the International Society to Advance Alzheimer's Research and Treatment
1760 (ISTAART) community, for advocating brain imaging genetics in Alzheimer's and aging
1761 research.